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ABSTRACT  
	 7	
The TP53 gene is the most commonly altered gene in human cancer. The majority of 
p53 mutations are missense and result in the accumulation of dysfunctional p53 protein 
in cancer cells. These mutant proteins frequently acquire neomorphic functions (defined 
as Gain of Function, GOF) including the induction of malignant properties of cancer 
cells, such as uncontrolled cell proliferation, metastasis and drug resistance. A number 
of evidence reveals that stabilization of mutant p53 proteins in tumours is required for 
their GOF properties, while reduction of mutant p53 levels mitigates the malignant 
potential of cancer cells. Thus, targeting mutant p53 represents a tumour attractive 
strategy for cancer therapy. Several small-molecule compounds that specifically target 
mutant p53 have been identified and are now in preclinical or clinical development. 
Some of them induce instability of mutant p53 proteins, leading to inhibition of multiple 
downstream pathways of GOF mutant p53. In this thesis, I tested a collection of FDA-
approved drugs to identify molecules able to reduce the levels of mutant p53 in a triple 
negative breast cancer cell line. This screening allowed the identification of statins as 
class of drugs strongly inhibiting mutant p53 accumulation. Further investigation 
demonstrated that mutant p53 protein stability depends on the activation of the 
metabolic mevalonate pathway and that statins inhibit mutant p53 GOF in cancer cells. 
Mechanistically, the mevalonate pathway intermediate geranylgeranyl pyrophosphate 
inhibits the Mdm2-dependent mutant p53 protein degradation. In particular, my data 
show that mutant p53 stability is controlled by geranylgeranylated proteins and that 
geranylgeranyl transferase inhibitors behave as statins. These results on a novel 
crosstalk between the metabolic mevalonate pathway and mutant p53 support the notion 
that these two signals are strongly intertwined and together concur to the malignant 
phenotype of different tumours. The data of this thesis provide the experimental-based 
rational for the use of mevalonate pathway inhibitors as adjuvant treatment in the 
therapy of tumours bearing sporadic or inherited mutations of p53.  
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INTRODUCTION  
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The tumour suppressor p53 
One of the most important signalling pathways against tumour formation and 
progression is the p53 tumour suppressor pathway. p53 was discovered in 1979 by three 
independent groups as an interacting partner of the viral SV40 T-antigen (Lane & 
Crawford, 1979) (Linzer & Levine, 1979) (Kress, May, Cassingena, & May, 1979). For 
almost a decade, p53 was considered to be a tumour antigen with transforming 
capabilities. Only during the late 1980s it was revealed that p53 is indeed a tumour 
suppressor and that the evidence for its supposed oncogenic functions had been 
erroneously collected from tumour-derived mutant clones (Weisz et al. 2007). 
Throughout about 30 years of intensive studies, extensive knowledge has been achieved 
on the p53 pathway and a great extent of complexity has been unveiled. Embedded 
within a complex signaling pathway, p53 in response to a variety of stress signals that 
originate both from external factors (such as γ-radiation, UV-light, DNA damaging 
agents etc) or internal once (oncogene activation, high levels of reactive oxygen species, 
ribonucleotide depletion etc.) acts essentially as a transcription factor able to promote 
the coordinated expression of an array of target genes that are the executors of p53-
induced cellular responses, such as cell cycle arrest, senescence or apoptosis (Levine 
and Oren, 2009) that may compromise genomic stability and promote neoplastic 
transformation (Figure1).  
Given its crucial role as key integrator in translating diverse stress signals into different 
cellular outcomes, p53 has been called “guardian of the genome” (Levine & Oren 2009; 
Müller et al. 2001).
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The tumour suppressor protein p53 is expressed at very low levels in normal cells but 
accumulates in response to stress. The E3 ubiquitin ligase, Mdm2, is the most critical 
regulator of p53 and is also a p53 target gene (Harris & Levine 2005; Brooks & Gu 
2006). Mdm2 is able to maintain p53 protein at low levels promoting its ubiquitylation 
and consequent proteasomal degradation (Haupt et al. 1997; Kubbutat et al. 1997). 
However under stress condition, the increase of p53 levels are accompanied by 
transcriptional upregulation of Mdm2 expression, which can in turn 
inhibit p53 dependent transcriptional activation, creating a negative feedback loop 
resulting in down-regulation of p53 activity (Figure 1). 
A complex role in the p53-Mdm2 loop is played by the Mdm2-related protein Mdmx 
(known as Mdm4 in mouse), which, although lacking ubiquitin ligase activity on its 
own, has been reported to complex with Mdm2 and stimulate its E3 activity towards 
Introduction 
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functions had been erroneously collected from tumour-derived mutant clones (Weisz 
et al., 2007). 
After more than thirty years of research, extensive knowledge has been more and 
more achieved regarding the complexity of the p53 pathway (figure 1). 
 
Figure 1. Simplified scheme of the p53 pathway. The p53–MDM2 feedback loop is the “heart” of the 
p53 pathway. Under normal conditions, it maintains constantly low steady-state p53 levels and activity. 
Various stress signals, related in many ways to carcinogenesis, impinge on this central loop to release 
p53 from MDM2-mediated inhibition. This increases p53 protein levels and activity, inducing various 
phenotypic changes. The nature of the phenotypic response to p53 activation is, at least partially, 
proportionate to the amplitude, duration and nature of the activating signal. Recent evidence indicates 
that p53 has an important role also in enabling the cell to adjust its metabolism in response to mild 
normal physiological fluctuations, including those in glucose and other nutrient levels, oxygen 
availability and reactive oxygen species levels. (Levine and Oren, 2009) 
 
p53 can be envisioned at the centre of a highly interconnected network that conveys 
and transduces signals, which can represent stress conditions. Indeed, these signals 
can originate from external factors (such as γ-rays, UV light, DNA damaging agents, 
…) or internal ones (like oncogene activation, high levels f reactive oxygen species 
(ROS), ribonucleotide depletion, …) and may compromise genomic stability and 
promote neoplastic transformation. In response to these stresses p53 becomes 
stabilized and activated, events that are regulated by a refined combination of post-
translational modifications and interactin  protein partners (Kruse and Gu, 2009). 
One of the most crucial steps is its evasion from the continuous ubiquitylation by its 
major E3 ubiquitin ligase Mdm2 and the subsequent degradation by the 26S 
proteasome (Haupt et al., 1997; Kubbutat et al., 1997). Once activated, p53 acts 
essentially as a transcription factor able to promote the coordinated expression of an 
array of target genes that are the executors of p53-induced cellular responses, such as 
cell cycle arrest, senescence or apoptosis (Levine and Oren, 2009). Although all these 
Figure 1. Simplified scheme of the p53 pa hway. The p53–Mdm2 feedback oop is the 
“heart” of the p53 pathway. Under normal conditions, it maintains constantly low steady-
state p53 levels and activity. Various stress signals, related in many ways to carcinogenesis, 
impinge on this central loop to release p53 from Mdm2-mediated inhibition. This increases 
p53 protein levels and activity, inducing various phenotypic changes. The nature of the 
phenotypic response to p53 activation is, at least partially, proportionate to the amplitude, 
duration and nature of the activating signal. Recent evidence indicates that p53 has an 
important role also in enabling the cell to adjust its metabolism i  response to mild normal 
physiological fluctuations, including those in glucose and other nutrient levels, oxygen 
availability and reactive oxygen species levels. (Levine and Oren, 2009) 
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p53, thus maintaining p53 at low levels under normal conditions (Linares et al. 2003).  
p53 undergoes a great variety of post-translational modifications, such as 
phosphorylation, acetylation and ubiquitination, that influence its stability and its 
transcriptional activity. Many kinases, (for example ATM, ATR, Chk1, Chk2, CK1, 
CK2, JNK, Erk, p38, Aurora Kinase A, GSK3β, HIPK2 and DYRK2) have been shown 
to phosphorylate p53 after DNA damage (Kruse & Gu 2009; Vousden & Prives 2009). 
The best-characterized p53 phosphorylations (Ser15, Thr18, Ser20 and Ser46) occur in 
the N-terminus of the protein and are know to upregulate p53’s transcriptional activity 
in response to stress condition; while Thr55, Ser376 and Ser378 residues seem to be 
constitutively phosphorylated in unstressed cells (Gatti et al. 2000; Waterman et al. 
1998). Moreover, p53 can be acetylated at several lysines by different histone acetyl-
transferases (HATs) such as p300/CBP (on Lys 370, 372, 373, 381 and 382) and PCAF 
(p300/CBP-associated factor) (on Lys320 and Lys305), which have been shown to 
acetylate p53 in response to DNA damaging agents, such as UV- and γ-irradiation 
(Carter & Vousden 2009). Thus, in response to a variety of stress stimuli, p53 is rapidly 
stabilized and activated through a complex repertoire of post-translational modifications 
and protein–protein interactions to allow both direct and indirect transactivation of 
many coding and non-coding genes (Kruse & Gu 2009). 
 
The p53 family 
For a long time, p53 was believed to be a unique protein without any paralogue. 
However, later it became clear that p53 belongs to a multigene family that includes 
other two members and also transcription factors, namely p63 and p73 (Kaghad et al. 
1997; Yang et al. 1998) that are structurally similar and functionally related to p53. 
Although all three proteins are able to bind to DNA in a sequence specific manner 
(recognizing similar consensus sequences) and have a similar modular organization, 
their primary structures do not share an elevated homology: it is about 30% for the 
whole sequence, but it reaches 65% when only the DNA binding domain is considered 
(IARC TP53 Database, www.p53.iarc.fr).  
As a consequence of the partial structural homology, p53 family members have some 
overlapping functions mediated by the transactivation of common target genes (Stiewe 
2007). Indeed, p63 and p73 are able to trigger apoptosis upon DNA damage and in 
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response to chemotherapeutic drugs (Yang & McKeon 2000; Lang et al. 2004; Lin et al. 
2009) and to induce senescence both in vitro and in vivo (Fang et al. 1999; Guo et al. 
2009). Recently, a critical role for p63 in metastasis suppression has emerged (Adorno, 
Cordenonsi, Montagner, Dupont, Wong, Hann, Solari, Bobisse, Rondina, Guzzardo, 
Anna R Parenti, et al. 2009; Muller et al. 2009). The silencing of p73 and p63 increases 
the transforming potential of p53-null mouse embryonic fibroblast (Lang et al. 2004). 
Consistently, analysis of the tumour predisposition of p63 and p73 heterozygous mice 
revealed a consistent connection with cancer: p63+/- and p73+/- mice develop 
spontaneous tumours and survive similarly to p53+/- mice (Flores et al. 2005). Even if 
there are not evidence of mutations that compromise their functions in cancer, p63 and 
p73 are aberrantly expressed in tumour. 
Thus the entire p53 family may be considered as a unique signaling network in which 
all p53 family proteins are involved in the response to oncogenic stress and 
physiological inputs, sharing also many oncosuppressive functions. 
 
Functional domains of p53 protein 
The human p53 gene span 20 Kbases on chromosome 17 (17p13.1) and consists of 11 
exons, which encode a protein of 393 residues (el-Deiry et al. 1992). As many other 
transcription factors, p53 has a modular structure composed by evolutionarily conserved 
functional domains: an N-terminal transactivation domain (aa 1-61), a proline-rich 
domain (aa 64-93), a central DNA-binding domain (aa 93-292), an oligomerization 
domain (aa 325-355) and a C-terminal regulatory domain (figure 2).  
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The N-terminal transactivation domain of p53 contains two acidic domains (TAD1), aa 
1-40 (Unger et al. 1993) and TAD2, aa 40-61 (Candau et al. 1997) interacting with the 
transcriptional machinery (Unger et al. 1993) such as TBP (TATA box binding protein), 
TAFs (TBP-associated factors) (Chang et al. 1995) and the transcriptional coactivators 
CBP (CREB binding protein) and p300 (Avantaggiati et al. 1997) (Scolnick et al. 1997). 
This region contains also the binding site for the major negative regulator of p53, the 
ubiquitin ligase Mdm2, and the related transcriptional repressor Mdmx (Toledo et al. 
2007). 
The transactivation domain is followed by a proline-rich domain (PRD, aa 64-93), 
which contains five repeats of the amino acid motif PXXP (P= proline; X= any amino 
acid) and it is required for p53 stabilization. Indeed, the prolyl isomerase Pin1 binds to 
Thr81-Pro82 site, upon Thr81 phosphorylation, and induces the isomerization of the 
peptide bond, leading to Mdm2 displacement  (Berger et al. 2005; Zacchi et al. 2002; 
Zheng et al. 2002). The central core of p53 contains its DNA binding domain (aa 93-
292), that recognizes and binds the p53-responsive element on DNA, and also proteins 
that positively affect p53 acitvity (e.g. 53BP1, Hzf, ASPP1 and ASPP2). The 
oligomerization domain (OD, aa 325-355) is required for the formation of a high-
affinity DNA binding and transcriptional competent p53 tetramer. 
The C-terminal domain of p53 contains several residues targeted by post-translational 
modifications that modulate p53 stability and function (Kruse & Gu 2009). In the C 
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Mutant p53 
Mutation or functional inactivation of the tumor suppressor p53 is an almost universal 
feature of human cancer. The frequencies of reported TP53 mutations vary 
considerably between cancer types, ranging from 10% in haematopoietic 
malignancies (Peller et al., 2003) to 50–70% in ovarian (Schuijer and Berns, 2003), 
colorectal (Iacopetta, 2003), and head and neck (Blons and Laurent-Puig, 2003) 
cancers. Whereas somatic TP53 mutations contribute to sporadic cancer, germline 
TP53 mutations cause Li-Fraumeni Syndrome (LFS), a rare type of cancer 
predisposition which is not associated with site-specific tumors, but rather with a 
variety of tumor types occurring at a relatively early age (Varley, 2003). 
Unlike most tumor-suppressor genes, which usually undergo gene-expression 
inactivation in carcinogenesis by deletions or truncating mutations, TP53 is frequently 
inactivated (74%) by missense mutations (IARC TP53 Database). As a consequence, 
in the vast majority of tumors, cells express a full-length mutant form of p53, which 
differs from the wild-type counterpart in a single amino acid substitution. 
Both germline mu ations and sporadic somati  mutations show the same distribution 
in the TP53 gene (Varley, 2003). Indeed, they are not randomly dispersed along the 
whole sequence, but are generally found in the region corresponding to the DBD of 
the protein. As shown in figure 3, almost a third of all missense mutations arise in six 
“hotspot” codons (Hollstein et al., 1991; Petitjean et al., 2007). Most TP53 mutations 
can be classified into two main categories according to their effect on the 
thermodynamic stability of the p53 protein (Bullock and Fersht, 2001). These two 
Figure 3. The distribution of reported missense mutations along the p53 sequence. The six most 
common hotspot mutations are highlighted in yellow for DNA-contact mutations, green for locally 
distorted mutants and blue for globally denatured mutants. The domain architecture of p53 is aligned 
below. TA, transactivation domain; PR, proline-rich domain; DBD, DNA binding domain; Tet, 
tetramerization domain; Reg, carboxy-terminal regulatory domain. Data derived from the IARC TP53 
Database. 
 
Figure 2. The distribution of reported missense mutations along the p53 sequence. The 
six most common hotspot mutations are highlighted in yellow for DNA-contact mutations, 
green for locally distorted mutants and blue for globally denatured mutants. The domain 
architecture of p53 is aligned below. TA, transactivation domain; PR, proline-rich domain; 
DBD DNA binding domain; Tet, tetramerization domain; Reg, carboxy-terminal regulatory 
domain. Data derived from the IARC TP53 Dat base. 
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terminus of p53 is present a cluster of three nuclear localization signals (NLS) that 
mediate the shuttling of the protein into the cell nucleus (Shaulsky et al., 1990). p53 
contains also two putative nuclear export signals (NES), one in the N-terminus (nNES, 
aa 11-27) and the other in the OD (cNES, aa 340-351)  (Stommel et al. 1999; Zhang & 
Xiong 2001). 
 
p53 isoforms  
Few years ago, it has been revealed the existence of a complex pattern of different p53 
isoforms due to use of several promoters and to alternative splicing (figure 3).  
                
 
 
The p53 protein can be codified from transcripts that can be initiated from two distinct 
sites upstream of exon 1 (P1 and P1’), but also from an internal promoter located in 
intron 4 (P2). The use of alternative promoters can lead to the expression of two 
different N-terminally truncated p53 proteins: Δ40p53 and Δ133p53. Δ40p53, which 
misses part of the transactivation domain (TAD1), can be obtained also by alternative 
initiation of translation or alternative splicing of the intron 2. The usage of P2 mediates 
the expression of Δ133p53, isoform that initiates at codon 133 and lacks the entire 
Introduction 
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(nNES, aa 11-27) and  the other in the OD (cNES, aa 340-351) (Stommel et al., 1999; 
Zhang and Xiong, 2001). For both NES, it has been proposed that when p53 needs to 
be activated, they are masked by the formation of the tetramer, or by direct 
phosphorylation by DNA-damage activate kinases. More generally, the 
oligomerization of p53 has been proposed as a mechanism that may regulate its 
nucleo-cytoplasmic transport by affecting the accessibility of the cNES but also of the 
NLS to their respective receptors (Stommel et al., 1999; Zhang and Xiong, 2001). 
 
 
p53 isoforms 
 
Few years ago, it has been revealed the existence of a complex pattern of different 
p53 isoforms due to use of several promoters and to alternative splicing (figure 3). 
 
Figure 3. (A) Scheme of the human p53 gene structure. Alternative splicing (α, β, γ) and alternative 
promoters (P1, P1’ and P2) are indicated. (B) Structural and functional domains of p53 protein 
isoforms. (Bourdon, 2007) 
 
The p53 protein can be codified from transcripts that can be initiated from two 
distinct sites upstream of exon 1 (P1 d P1’), but lso from an internal promoter 
located in intron 4 (P2). The use of alternative promoters can le d to the expression of 
two different N-terminally truncated p53 proteins: Δ40p53 and Δ133p53. Δ40p53, 
which misses part of the transactivation domain (TAD1), can be obtained also by 
alternative initiation of translation or alternative splicing of the intron 2. The usage of 
P2 mediates the expression of Δ133p53, isoform that initiates at codon 133 and lacks 
Figure 3. (A) Scheme of the human p53 gene structure. Altrenative splicing ( α, β,γ ) and 
alternative promoters (P1, P1’, P2 ) are indicated. (B) Stuctural and functional domains of 
p53 protein isoforms.  
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transactivation domain (TAD1 and TAD2), the proline rich domain and part of the 
DNA-binding domain. Moreover, the alternative splicing of intron 9 can produce three 
isoforms different in their C-terminus: p53 (or p53α), p53β and p53γ, with p53β and 
p53γ isoforms lacking the oligomerization domain (Bourdon et al. 2005; Ghosh et al. 
2004). Interestingly, an additional p53 isoform (Δp53) has been described, which is 
characterized by a deletion of 66 aminoacids within the core domain (corresponding to 
aa 257-322) and showed a transcriptional activity different from that of full-length p53 
(Rohaly et al. 2005). Indeed, it induces only p53 target genes involved in cell- cycle 
arrest, thereby participating in a specific intra-S phase checkpoint.  
Until now, the spatial and temporal expression levels of the different p53 isoforms are 
largely unknown and their functional roles still await further characterization.  
 
 
Tumour suppressor activities of p53  
Once activated, the transcription factor p53 exerts its activity by directly binding to 
specific target sequences on DNA to regulate the expression of several genes involved 
in a wide variety of biological process such as DNA repair, development, cell death, 
metabolism, senescence to prevent tumourgenesis and to maintain genomic integrity 
(Levine & Oren 2009). 
Among the tumour suppressive activities fostered by p53, apoptosis is undoubtedly the 
most studied mechanism in vitro and in vivo. Under genotoxic stress, activated p53 
rapidly regulates the expression of pro-apoptotic members of this pathway such as, Bax, 
Bid, Puma, Noxa, p53AIP1 (Nakano & Vousden 2001) and repress anti-apoptotic genes 
Bcl2 and Bcl-xL (Green & Kroemer 2009; Chipuk et al. 2004) with consequent 
permeabilization of the mitochondrial outer membrane and release of cytocrome c 
(Vousden, 2005). Furthermore, recent studies have shown that p53 is also able to induce 
apoptosis in a transcription-independent way (Vaseva & Moll 2009); indeed, a fraction 
of p53 is able to translocate to mitochondria, where it directly binds and inhibits anti-
apoptotic Bcl-xL and Bcl-2 factors, inducing release of cytochrome c (Mihara et al. 
2003).  
The tumour suppressor p53 was found also to regulate apoptosis in a Ca2+-dependent 
manner at the endoplasmic reticulum. Mechanistically, p53, upon activation induced by 
	 16	
genotoxic stress, was found directly to bind to the sarco/ER Ca2+-ATPase (SERCA) 
pump at the ER, changing its oxidative state and thus leading to an increased Ca2+ load, 
followed by an enhanced transfer to mitochondria. The consequent mitochondrial Ca2+ 
overload causes in turn alterations in the morphology of this organelle and induction of 
apoptosis (Giorgi et al. 2015). 
Interestingly, in response to oxidative stress, the tumour suppressor p53 can induce 
necrosis instead of apoptosis. Excess cytosolic Ca2+ and ROS induce p53 activation 
and its mitochondrial translocation, leading to VDAC oligomerization and permeability 
transition pore (PTP) formation, causing H2O intake, swelling of mitochondria and 
necrosis (Vaseva et al. 2012). According to cell type and the kind of stress, the 
activation of the p53 pathway can also induce cell cycle arrest, at different cell cycle 
checkpoints (G1 or G2), mostly promoting the induction of three critical target genes: 
p21, 14-3-3σ and GADD45 to prevent the propagation and accumulation of DNA 
damage and mutations (Kastan et al. 1992; Hermeking et al. 1997; El-Deiry et al. 1993). 
Induction of senescence is another important function of the tumour suppressor p53. 
Indeed, in response to oncogenic stress and chemotherapy, p53 activation can also lead 
to cell cycle arrest and senescence instead of apoptosis and necrosis. Interestingly, it 
was recently reported that reactivation of p53 in p53-deficient tumours completely 
represses tumour growth through senescence in a mouse liver tumour model (Xue et al. 
2007). In the first moment after the oncogenic stimulus, p53 activation leads to 
senescence by inducing p21, while the permanent growth arrest is then maintained by 
p16 expression (Chen et al. 2005; Ventura et al. 2007). 
In the recent years it has also been found that p53 can promote the process of autophagy 
through different mechanism, which may contribute to the role of p53 in tumour 
prevention. When exposed to stress, nuclear p53 can induce autophagy by inhibiting the 
master negative regulator of autophagy mTOR, acting at multiple levels of the AMPK-
mTOR axis (Feng et al. 2005; Feng et al. 2007). Furthermore, p53 is also able to induce 
autophagy regulating the expression of genes such as DRAM, PUMA, Ei24 (Crighton et 
al. 2006; Zhao et al. 2012). Regulation of cell cycle arrest, senescence and apoptosis are 
the most well studied functions of p53, which have been accepted as the main 
mechanisms for p53 to function as a tumour suppressor. Interestingly, recent studies 
have revealed that p53 regulates cellular energy metabolism (Bensaad et al. 2006; 
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Vousden & Ryan 2009), and antioxidant defense (Budanov et al. 2004) which 
contribute greatly to the role of p53 in tumour suppression. 
The activity of p53 in metabolism involves several aspects, spanning from oxidative 
stress regulation to the orchestration of glucose metabolism (Maddocks & Vousden 
2011) resulting from a coordination of transcriptional and cytoplasmic activities of p53. 
The tumour suppressor is able to promotes both the mitochondrial oxidative 
phosphorylation (OXPHOS), activating synthesis of cytochrome c oxidase 2 (SCO2) 
expression, cytochrome c oxidase (COX) I subunit, and AIF (Vahsen et al. 2004) and 
down-regulates glycolysis in cells to maintain the homeostasis of energy metabolism. 
The reactive oxygen species (ROS), produced by the enhancement of OXPHOS, could 
be detrimental for cell survival, thus p53 transcriptionally induces a group of 
antioxidant genes, including sestrins 1/2, TIGAR, MnSOD, GPX1, ALDH4, GLS2, and 
Parkin (Hu et al. 2010; Suzuki et al. 2010; Budanov et al. 2010; Pani & Galeotti 2011), 
to reduce the intracellular levels of ROS and prevent DNA damage induced by ROS 
(Liang et al. 2013; Bensaad & Vousden 2007). Interestingly, it has been recently 
demonstrated that p53 binds to and reduces the activity of glucose-6-phosphate 
dehydrogenase, a rate-limiting enzyme in the pentose phosphate pathway, to down-
regulate glucose metabolism and the Warburg effect (Jiang et al. 2011). 
Thus, the tumour suppressor p53 is a transcription factor that in response to a plethora 
of stress stimuli activates a complex and context-dependent cellular response, ultimately 
protecting genome integrity and preventing tumourgenesis. 
 
 
Mutant p53 
The TP53 gene is frequently altered gene in human cancers (Cyriac Kandoth, Michael 
D. McLellan, Fabio Vandin, Kai Ye 2013). Mutations in the TP53 gene occur in over 
50% of all tumours with frequencies that vary considerably between cancer types, 
raging from 10% in hematopoietic malignancies (Peller et al. 2003), to 50-70% in 
ovarian (Schuijer & Berns 2003), colorectal (Iacopetta 2003), and head neck cancers 
(Blons & Laurent-Puig 2003). Clinical studies revealed that certain mutations in the 
TP53 gene have been associated with poor clinical outcome in a variety of 
malignancies, including breast cancer, and are also associated with an even worse 
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prognosis (Olivier et al. 2006; Petitjean et al. 2007). TP53 gene is mutated in ∼35% of 
total breast cancer, but this percentage is increased to 54% in triple negative breast 
cancers (TNBC) (Polyak & Metzger Filho 2012).  
Whereas somatic TP53 mutations contribute to sporadic cancer, germline TP53 
mutations cause a rare type of cancer predisposition known as Li-Fraumeni Syndrome 
(LFS), which is not associated with site-specific tumours, but rather with a variety of 
tumour types occurring at a relatively early age (Li and Fraumeni, 1969).  
Unlike most tumour-suppressor genes that usually undergo gene-expression inactivation 
in carcinogenesis by deletions or truncating mutations, the TP53 gene is frequently 
inactivated (74%) by missense mutations (IARC TP53 Database). As a consequence, in 
the vast majority of tumours, cells express a stable full-length mutant form of p53, 
which differs from the wild-type counterpart in a single amino acid substitution. Most 
of these missense mutations occur within the DNA binding domain (DBD) and 
particularly six “hot spot” mutated residues have been identified (Hollstein et al., 1991) 
and classified into two main categories according to their effect on the thermodynamic 
stability of the p53 protein (Bullock and Fersht, 2001). These two categories are 
commonly referred to as “DNA‐contact” mutant, where mutations occur on amino acids 
directly binding to the DNA (e.g. p53R273H and p53R280K) and “conformational” mutant 
in which the structure of p53 protein is altered by mutations, thus abolishing its DNA-
binding ability ( e.g. p53R175H and p53R249S) (Joerger & Fersht 2008). 
The functional effects of TP53 mutations can be classified into three non-mutually 
exclusive groups (Brosh and Rotter, 2009) (Figure 4):  
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. Loss of functions (LOF): most missense mutations have abrogated the tumour 
suppressor functions of the affected allele. This “loss of function” is due to 
reduction of p53 binding to its consensus DNA sequence and, consequently, 
hampered transcriptional activation of p53 target genes (Kato et al., 2003) 
(Figure 4).  
. Dominant-negative effect: mutant p53 is capable of inhibiting, to varying 
degrees, the function of the wild-type protein encoded by the second allele. This 
“dominant-negative” effect is achieved by oligomerization of mutant and wild-
type proteins, forming a heterotetramer defective in sequence specific DNA 
binding (Dittmer et al., 1993; Milner and Medcalf, 1991). Furthermore, 
p53mutations are usually followed by loss of heterozygosity in human cancer, 
leading to deletion or mutation of the rest wild-type p53 allele (Figure 4).  
. Gain of functions (GOF): the aberrant expression of several missense mutant 
p53 proteins leads the cells to acquire a complex repertoire of oncogenic traits 
such as increased proliferation, increased migration and resistance to 
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Similarly, mutant p53 was shown to enhance the NF-κB 
response to tumour necrosis factor α (TNFα) in cancer 
cells94, and to transcriptionally activate NFKB2 (REF. 95). 
These data combined suggest that TP53 mutations, by 
antagonizing the ability of wild-type p53 to inhibit the 
expression of inflammatory genes and by activating 
the pro-inflammatory NF-κB pathway, may promote 
tumorigenesis in the context of chronic inflammation.
As mentioned earlier, several gain-of-function prop-
erties of p53 mutants are mediated not through DNA 
binding, but rather through modulation of non-tran-
scriptional processes. A recent study revealed that the 
hotspot DNA-contact mutants p53R248W and p53R273H can 
bind MRE11, an upstream component of the ataxia- 
telangiectasia mutated (ATM)-dependent DNA-damage 
response pathway and, consequently, inhibit the cellu-
lar response to DNA double-stranded breaks52. The 
apparent phenotypes in mutant Trp53 knock-in mice 
are augmented genetic instability, increased levels of 
interchromosomal rearrangements in pre-malignant 
thymocytes and development of lymphomas, which 
were not observed in Trp53-null mice52. The clinical 
implications of this finding are perhaps the enhanced 
resistance of some tumours harbouring mutant p53 to 
cancer therapies that induce double-stranded breaks27 
and the observed association between mutant p53 and 
chromosomal instability in human cancers96,97.
Taken together, it seems that modulation of gene tran-
scription and interference with pivotal signalling path-
ways are important mechanisms by which p53 mutants 
exert their oncogenic functions. As discussed in the fol-
lowing section, the interaction of mutant p53 with DNA, 
with DNA-binding proteins and with the DNA-damage 
response network may account for the emerging tran-
scriptional signatures associated with TP53 mutations 
in human malignancies.
Gene signatures associated with TP53 mutations
Gene-expression signatures can be used to develop 
genomic tests that may provide better predictions of 
clinical outcome than the traditional clinical and patho-
logical standards98. Whole-genome expression profiles of 
tumours provide more information than histopathologi-
cal examination and other classical biomarkers, and ena-
bles the sub-typing of tumours into distinct classes with 
different prognostic characteristics, and, importantly, 
with varying responses to therapeutic drugs. Therefore, 
expression signatures afford opportunities to match 
therapies to individual patients99.
When analyzing genome-wide expression profiles 
across different in vitro studies, it is hard to find common 
signatures associated with TP53 mutations, probably 
owing to variations in the type of mutant analyzed, the cel-
lular system and other technical variables. The expression 
profiles of human tumours are even more heterogeneous 
owing to variability in the patients’ background, type of 
TP53 mutation, TP53 LOH and the proportion of contam-
inating stroma. Accordingly, widely recognized mutant 
p53 target genes (such as MDR1 (REF. 28) and MYC100) 
are rarely found in these signatures. However, some pat-
terns begin to emerge, even when the effects of different 
p53 mutants are collectively evaluated. For example, an 
expression signature consisting of 95 genes that were uni-
versally modulated by four different hotspot mutants in 
prostate cancer cells was recently discovered101. Similarly, 
three hotspot mutants ectopically expressed in TP53-null 
lung cancer cells induce a common gain-of-function tran-
scriptional signature comprising more than 100 genes95,102. 
These results indicate common transcriptional activities 
for different p53 mutants, and provide a basis for the asso-
ciation of TP53 mutations with transcriptional signatures 
in human tumours. Accordingly, expression signatures 
associated with TP53 mutations were recently identi-
fied using large sets of breast cancer samples. Specifically, 
strong association was found between TP53 mutations and 
expression signatures that were previously demonstrated 
to predict patient survival103–105. Tumours with TP53 muta-
tions were mostly classified into the basal-like or ERBB2-
like subgroups. Tumours from the basal-like subgroup 
display an expression profile characteristic of breast basal 
epithelium, including high expression of keratin 5 and lam-
inin, and are usually oestrogen receptor- and progesterone 
receptor-negative. High expression of genes associ-
ated with oncogenic ERBB2 amplification characterizes 
tumours from the ERBB2-like category. Importantly, the 
basal-like and ERBB2-like subgroups are associated with 
Box 2 | Functional impact of TP53 mutations
The phenotypic effects of TP53 mutations can be classified into three non-mutually 
exclusive groups7,35:
First, most mutations observed in human tumours abrogate or attenuate the binding of 
p53 to its consensus DNA sequence and, consequently, impede the transcriptional 
activation of p53 target genes17. In genetics, these mutations can be defined as 
hypomorphic or amorphic, for partial or complete loss of function, respectively. Loss of 
function (LOF) is frequent among missense mutants, but is particularly relevant to 
truncating, splicing and nonsense mutations, as well as to gene deletions.
Second, most missense mutations, but usually not the other types of mutations, also 
produce a full-length mutant p53 capable of inhibiting, to varying degrees, the function 
of the wild-type protein encoded by the second allele. This (antimorphic) 
dominant-negative (DN) effect is achieved by oligomerization of the mutant and 
wild-type proteins, forming a heterotetramer defective in sequence-specific DNA 
binding18-20.
Finally, several mutations were shown to confer mutant p53 with new functions that are 
independent of wild-type p53. These (neomorphic) gain-of-function (GOF) properties can 
be experimentally demonstrated in the absence of a functional wild-type p53. The first 
such experimental settings 
used overexpression of 
mutant p53 in TP53-null 
cells21-23. More advanced and 
physiological systems 
include knockdown of 
endogenous mutant p53 in 
cell lines that do not express 
wild-type p53 (REFS 56,57) 
or comparison of mutant 
Trp53 knock-in mice  
with Trp53-null mice50-52. 
Most gain-of-function 
properties are believed to 
stem from binding of mutant 
p53 to cellular proteins such 
as transcription factors and, 
consequently, alteration in 
their activity.
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Figure 4. Schematic representation of the functional impacts of TP53 mutations. 
LOF (loss-of-function); DN (dominant-negative effects); GOF (gain-of-function). From 
Brosh and Rotter, 2009. 
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chemotherapy treatment. 
.  
Gain-of-Function of mutant p53 in cancers  
 As the field of p53 research evolves, it is increasingly evident that many mutant p53 
forms not only lose their tumour suppressive functions and acquire dominant‐negative 
activities, but also gain oncogenic properties that can actively contribute to various 
aspects of tumour progression such as migration and invasion, angiogesnsis and 
chemioresistance, rendering the tumour cells harboring mutant p53 more aggressive. 
(figure 5). 
 
 
 
In these years numerous evidences clearly established the pro-oncogenic role of p53 
missense mutants p53 (Oren & Rotter 2010). The first evidence that mutant p53 may 
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mice developed tumours at an earlier age53. Therefore, 
loss of INK4A expression, a common oncogenic event, 
may also contribute to cancer development by stabilizing 
mutant p53.
Mutant p53 is known to interact with heat-shock 
proteins such as HSP90 and HSP70 (REFS 61–64). In this 
context, some insights into the accumulation of mutant 
p53 in tumours and its phenotypic consequences were 
recently obtained. For instance, wild-type and mutant 
p53 were shown to have opposite dependencies on the 
molecular chaperone HSP90. Whereas wild-type p53 
accumulated following HSP90 inhibition, the protein 
level of mutant p53 was reduced. In line with the gain-
of-function hypothesis, mutant p53 destabilization upon 
HSP90 inhibition was accompanied by cell death65. 
Additionally, recent studies investigated the involvement 
of HSP90, HSP70 and the ubiquitin-ligase CHIP (also 
known as STUB1) in the regulation of mutant p53 sta-
bility49,66, demonstrating that HSP90 inhibition increases 
the unfolded fraction of the mutant p53 molecules, which 
are then bound by HSP70 and marked for degradation 
by CHIP. Because HSP90 is frequently over-activated 
in tumours67, the dependency of mutant p53 on HSP90 
may account for its tumour-specific accumulation and 
underlie the therapeutic potential of HSP90 inhibitors68.
The subcellular localization of mutant p53 is 
another parameter that affects its oncogenic proper-
ties. Although mutant p53 usually accumulates in the 
nucleus of cancer cells43,69,70, in some cases it localizes 
to the cytoplasm, depending on the type of mutant, 
the cellular context and a variety of stress signals that 
modulate p53 localization48,69. As with wild-type p53, 
MDM2-dependent and MDM2-independent ubiq-
uitylation seems to regulate nuclear export of p53 
mutants, and especially of conformational mutants, 
probably by exposing their C-terminal nuclear export 
signal48,71. Interestingly, a recent study demonstrated 
that cytoplasmic p53 mutants can inhibit autophagy 
in cancer cells72. For each of 22 mutant p53 forms 
analyzed, a unique localization pattern was observed, 
from almost exclusively nuclear (for example, p53R282W) 
to almost exclusively cytosolic (for example, p53R273H). 
On the single-cell level, all p53 mutants were com-
petent at inhibiting autophagy when localized to the 
cytosol, although the inhibitory effect on the entire cell 
population was much more pronounced for mutants 
with predominantly cytosolic localization. Chronic 
suppression of autophagy was demonstrated to facili-
tate tumorigenesis, and several proteins that promote 
autophagy are considered tumour suppressors73. 
Hence, inhibition of autophagy may constitute a new 
oncogenic property of p53 mutants, and highlights the 
importance of subcellular localization of p53 mutants 
in tumours.
Mutant p53 gain-of-function properties
Interaction with p63 and p73. Since the discovery 
of mutant p53 oncogenic potential21–23,74,75, numer-
ous gain-of-function properties were demonstrated 
and a variety of underlying mechanisms were pro-
posed7,20,76,77 (FIG. 1). However, recent findings not only 
broaden the array of gain-of-function properties, but 
also highlight their relevance to tumorigenesis. A piv-
otal gain-of-function mechanism is the ability of com-
mon p53 mutants to bind and inactivate p53 family 
members, p63 and p73 (REFS 78,79). These transcrip-
tion factors have key roles during development and 
can be expressed as several splice variants with distinct 
and even antagonistic functions80. Importantly, there is 
a substantial amount of data to support the role of the 
transactivation-potent variants of p63 and p73 in sup-
pressing tumorigenesis80. Moreover, analysis of mouse 
models demonstrated that p63 and p73 can partially 
compensate for deletion of Trp53 as Trp53+/–Trp63+/– 
mice and Trp53+/–Trp73+/– mice have reduced survival 
and increased metastatic rate compared with Trp53+/– 
mice81. Therefore, inhibition of p63 and p73 function 
is considered a key mechanism for mutant p53 gain 
of function82,83. Evidence supporting this notion has 
come from the recently developed knock-in mouse 
model in which p53R172H was shown to bind p63 and 
p73 in tumour-derived cell lines, consequently inhibit-
ing their abilities to induce cell-cycle arrest and sup-
press focus formation50. The capacity of different p53 
mutants to bind p73 was shown to be significantly 
influenced by the site of mutation as well as by the 
Figure 1 | Selected oncogenic properties of mutant p53 and their underlying 
mechanisms. The inner circle (shaded blue) represents oncogenic phenotypes 
associated with the activities of mutant p53 proteins. The outer circle depicts key 
mechanistic properties of p53 mutants that underlie the phenotypes listed in the inner 
circle. Note that each of the phenotypic effects can be attributed to almost each of the 
mechanistic properties; hence the inner blue circle can be freely rotated. ATM, ataxia-
telangiectasia mutated; NF-κB, nuclear factor-κB; VDR, vitamin D receptor.
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Figure 5. Selected oncogenic properties of mutant p53 and their underlying mechanisms. 
The inner circle (sh ded blue) represents oncogenic phenotyp s associated with the activities 
of mutant p53 proteins. The outer circle depicts key mechanistic properties of p53 mutants that 
underlie the phenotypes listed in the inner circle. Each of the phenotypic effects can be 
attributed to almost each of the mechanistic properties; hence the inner blue circle ca  be 
freely rotated. (Brosh and Rotter, 2009) 
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show neomorphic gain of functions, was proved from the findings that the introduction 
of mutant p53 protein in p53-null tumour cells greatly increased the oncogenic potential 
of those cells in nude mice (Wolf et al. 1984; Dittmer et al. 1993). Mutant p53 was also 
shown to cooperate in oncogenesis with activated oncogenic Ras, both in primary 
mouse embryo fibroblasts (MEFs) (Lang et al. 2004) and  in vivo experiments, 
demonstrating that this cooperation increased tumour formation and progression with 
elevated rates of metastasis (Caulin et al. 2007; Jackson et al. 2005).  
Although p53 knockout mice are highly tumour prone, these lesions do not metastasize 
frequently nor generally display invasive pathology (Attardi & Jacks 1999). On the 
contrary, knock-in mouse models harboring two tumour-derived mutants of p53 
(equivalent to p53R175H and p53R273H in humans), display an altered tumours spectrum 
and more metastatic tumours when compared to p53 null mice (Olive et al. 2004; Lang 
et al. 2004). In addition it was unveiled, that mouse embryonic fibroblasts (MEFs) from 
mice with one or two copies of the p53515A allele (corresponding to the p53R175H hot spot 
mutation in human cancers) showed increased growth rates than p53+/- and p53-/- cells. 
This suggests that the p53515A mutation gives to cells a growth advantage, allowing cells 
to bypass contact inhibition.  
More recently, mutant p53 was found to enhance the metastatic potential of human 
tumour cell lines by facilitating cell migration and invasion (Adorno, Cordenonsi, 
Montagner, Dupont, Wong, Hann, Solari, Bobisse, Rondina, Guzzardo, Anna R Parenti, 
et al. 2009; Dhar et al. 2008; Müller et al. 2001).  
One distinctive feature of many p53 mutants is the ability to confer an elevated 
resistance to cells to a variety of pro-apoptotic signals such as cMyc-induced apoptosis 
in leukemic cells (Lotem & Sachs 1995). Overexpression of various tumour-associated 
mutant p53, compromise the efficacy of cancer chemotherapy rendering some cell types 
more resistant to therapeutic drugs such as doxorubicin, etoposide, and cisplatin (Bossi 
et al. 2006; Blandino et al. 1999; Li et al. 1998). The antiapoptotic activities of mutant 
p53 may thus not only accelerate tumour progression but also hinder the response of 
cancer patients to anticancer therapy.  
Several p53 mutations were reported to disrupt normal spindle checkpoint control, 
leading to genomic instability, manifested by inter-chromosomal translocations 
(Gualberto et al. 1998). The existence of this connection was established also in vivo 
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(Caulin et al. 2007; Hingorani et al. 2005). 
Alterations in cellular metabolism (metabolic reprogramming) are known to be a 
hallmark of cancer cells and a key contributor to tumour development (Hanahan & 
Weinberg 2011; Haupt et al. 1997; Feng et al. 2007; Levine & Puzio-Kuter 2010). 
Recently, it was demonstrated that stimulation of the Warburg effect (or aerobic 
glycolysis), the best-characterized metabolic change observed in cancer, is a crucial 
GOF of tumour-associated mutant p53. The Warburg effect is a phenomenon in which 
most tumour cells primarily utilize glycolysis for their energy, even under normal 
oxygen concentrations and is characterized by a much higher rate of glucose uptake and 
higher lactate production in tumour cells compared with normal cells (Feng et al. 2007; 
Haupt et al. 1997; WARBURG 1956). Mechanistically, mutant p53, both in cultured 
cells and knock-in mice, stimulates the Warburg effect mainly through promoting the 
translocation of GLUT1 (glucose transporter 1) to the plasma membrane (PM). This 
effect has been proved to be mediated by RhoA and its downstream effector ROCK  
(Rho-associated protein kinase) (Zhang et al. 2013). 
Recent studies showed that mutant p53 is also involved in the disruption of mammary 
tissue architecture via the mevalonate pathway, a metabolic pathway responsible for de 
novo cholesterol biosynthesis. It was observed that non malignant breast epithelial cells, 
in three dimensional culture model (3D), form spheroids reminiscent of acinar 
structures found in vivo, whereas breast cancer cells display highly disorganized 
morphology. Interestingly, it was unveiled that expression of mutant p53 in non-
malignant mammary epithelial cells is sufficient to induce an alteration of the three-
dimensional architecture of breast acini, disrupting their morphology in 3D cultures 
(Freed-Pastor et al., 2012). In particular, through a genome-wide expression analysis the 
mevalonate pathway was identified as significantly upregulated by mutant p53 and 
experiment performed with supplement of statins and sterol biosynthesis intermediates, 
reveal that this pathway is both necessary and sufficient for the phenotypic effects of 
mutant p53 on breast tissue architecture (Freed-Pastor et al. 2012). 
 
Mechanisms of mutant p53 Gain-of-function 
Several mechanisms of mutant p53 GOF have been described and can be subdivided in 
three main categories (Figure 5): 
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Mutant p53 binds to DNA to alter gene expression  
Despite mutant p53 proteins are unable to recognize wt-p53 consensus on DNA (Kato et 
al., 2003), modulation of gene transcription by mutant p53 is well documented and the 
list of its target genes is constantly growing (Brosh and Rotter, 2010). Mut-p53 proteins 
typically retain an intact transactivation domain (TAD), which may still operate exactly 
as it does within the wt-p53 protein (Lin et al. 1995), but can now be targeted to 
different sites on the chromatin. More evidences unveiled that several p53 mutants, 
although defective in sequence-specific DNA binding, retain the ability to bind specific 
non-B DNA structures with high affinity, even if different mutants bind various DNA 
structures through distinct mechanisms and with different affinities (Gohler et al., 
2005). Therefore, the specificity of mutant p53 to certain regulatory sequences is 
perhaps mediated by preferential binding to structural DNA motifs and not consensus 
sequences.  
 
Mutant p53 binds to transcription factors to regulate their functions 
Aberrant transcriptional regulation is a major event in human cancers, and this may 
occur through unscheduled activity of specific transcription factors, or aberrant 
recruitment of transcription co-activators, thus regulating their uncontrolled gene 
activation or repression. It has been reported that mutant p53 can interact with several 
transcription factors to enhance or prevent their activities operating as a co-factor able 
to sustain the expression of several pro-oncogenic genes. 
A central point in the mutant p53 gain‐of‐function mechanisms is the ability of p53 
mutants to bind and inactivate the p53 family members p63 and p73 (Di Como et al. 
1999; Gaiddon et al. 2001). Evidence supporting this notion, besides numerously 
experiment in cells, has come from the recently developed knock‐in mouse model 
expressing mutant p53 isoform (p53R172H ) which was shown to bind p63 and p73, 
consequently inhibiting their abilities to induce cell‐cycle arrest and to suppress tumour 
formation (Lang et al. 2004). p63 and p73 proteins bind to and activate many wild-type 
p53 target genes, and mediate cell cycle arrest, apoptosis, and senescence in response to 
stress. On the contrary mut-p53 proteins can engage in direct protein–protein 
interactions with p73 and p63, rendering them transcriptionally inactive (Marin et al. 
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2000; Strano et al. 2002). Consequently, genes that are normally controlled by p63 or 
p73 will become deregulated. Moreover, the p73‐binding capacity, is correlated with 
the ability of p53 mutants to protect cells from chemotherapeutic agents and, 
accordingly, with less favorable response to chemo‐radiotherapy in patients with head 
and neck cancer (Li & Prives 2007). However, the interaction between mut-p53 and 
p63/p73 can be regulated by cell-intrinsic and extrinsic signals and by additional partner 
proteins. In particular, in breast cancer cells, mutant p53 acts as a molecular switch for 
TGF-β-induced metastasis by curbing the p63 transcriptional activity through the 
formation of a ternary complex with Smad proteins (mutant p53/p63/Smad) (Adorno et 
al., 2009).   
In particular, mutant p53 has been found to enhance migration, through inhibition of the 
p63-mediated transcriptional induction of metastasis suppressor genes (Sharp1 and 
CCNG2). Consistently these genes were found associate with metastasis risk in a large 
cohort of breast cancer patients (Adorno, Cordenonsi, Montagner, Dupont, Wong, 
Hann, Solari, Bobisse, Rondina, Guzzardo, Anna R Parenti, et al. 2009).  
Nevertheless, more evidences unveiled that mut-p53 binds to several transcription 
factors to enhance their activity. The transcription factor NF-Y, was previously shown 
to associate with mutant p53, as well as wild-type p53, and regulate the transcriptional 
activation of cell cycle-regulated genes (cyclin A, cyclin B, CDC25C, and CDK1) (Di 
Agostino et al. 2006). Conversely to wild-type p53, which recruits HDAC1 on the 
promoters of NF-Y target genes, mutant p53/NF-Y complex is associated to p300 upon 
adriamycin treatment (Di Agostino et al. 2006) (Figure 6b). This complex was proposed 
to support the growth promoting properties of mutant p53 as well as the 
chemoresistance of some mutant p53 bearing tumours (Aas et al. 1996; Bergh et al. 
1995; Lu & El-Deiry 2009). Moreover, very recently studies unveiled that the effect of 
the cross-talk between NF-YB and mutant p53 is maximized by the transcriptional co-
activator YAP (Yes associated protein), with profound impact on cell proliferation. In 
particular, YAP physically interacts with mut-p53 proteins and promotes its binding to 
the heterotrimeric transcription factor NF-Y thus increasing cell proliferation (S. Di 
Agostino et al. 2015). 
Interestingly, it has been reported that mutant p53 expression leads to high expression 
of sterol biosynthesis genes in human breast tumours. Indeed, mutant p53 is associated 
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with sterol responsive elements (SRE) within promoters of sterol-regulated genes, 
acting as transcriptional coactivator for the sterol regulatory element-binding protein 
transcription factors, SREBP (Freed-Pastor et al. 2012) to enhance the expression of 
many mevalonate pathway genes and genes involved in protein prenylation (e.g. 
HMGCR, HMGCS1, GGT-1)(Figure 6a). 
 
 
 
 
Downstream of the mevalonate pathway act the pro-oncogenic transcription co-
activators YAP/TAZ, effectors of the Hippo pathway (Sorrentino et al). In this context, 
missense mutant-p53 and SREBP trigger unscheduled activation of YAP/TAZ, in both 
cancer cells and human primary tumours, by sustaining the mevalonate pathway. For 
this reason, YAP/TAZ have been suggested as critical effector of the pro-oncogenic 
function of mutant p53 (Sorrentino et al. 2014).  
Another example of transcription factor able to interact with mutant p53 is the vitamin 
D receptor (VDR). By ChIP-on-chip analysis, the VDR response element was found to 
be over-represented in promoters bound by mutant p53 R175H. Mutant p53 is indeed 
Figure 6. Mutant p53 binds to numerous proteins to enhance or inhibit their function. 
a)Mutant p53 enhance SREBP function to increase sterol biosyntesis, leading to enhanced 
anchorage-independent growth and disruption of mammary tissue architeture. b) In response 
to DNA damage,TopBP1 and PLK2 facilitate the recruitment of mutant p53 toNF-Y, leading 
to increased expression of genes involved in proliferation (Muller and Vousden 2013). 
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recruited on VDR-regulated genes and modulates their expression, thus converting 
vitamin D receptor into an anti-apoptotic factor (Stambolsky et al. 2010). 
 
Mutant p53 interacts with other proteins  
A crucial role in mut-p53 GOF is certainly played by protein-protein interaction with 
partners other than DNA binding transcription factors. Indeed, mut-p53 can bind 
MRe11, a DNA nuclease required for homologous recombination DNA repair, and 
consequently inhibits the cellular response to DNA double‐stranded breaks, promoting 
genomic instability and tumour progression (Song et al. 2007). Another example is the 
interaction between p53 and topoisomerase I (Topo I) which leads to an increase in 
aberrant homologous DNA recombination events and mutagenic DNA rearrangements, 
spawning an additional type of genomic instability (Restle et al. 2008). Moreover, it has 
been identified that promyelocytic leukemia (PML) protein, a well known tumour 
suppressor, is also a mutant p53 interacting protein (Haupt et al. 2009). 
Interestingly, the prolyl isomerase Pin1, which regulates conformational changes of 
proteins to affect their stability and activity, was reported to be an additional mutant p53 
binding protein. In particular, it has been described that Pin1 binds to phosphorylated 
mutant-p53 (on Ser46 and Ser315) in breast cancer cell lines, and together regulate a 
transcriptional program of 10 genes (DEPDC1, BUB1, CENPA, CCNE2, FAM64A, 
C21orf45, CPSF6, EPB41L4B, NCAPH, WDR67) that promotes migration and 
metastasis formation in vivo and correlates with poor prognosis in triple negative breast 
cancer patients. Moreover, Pin1 was demonstrated to enhance the oncogenic activity of 
mutant p53 through mutant p53-dependent inhibition of p63 (Javier E. Girardini et al. 
2011). This suggest that Pin1 contributes to mutant p53 oncogenic properties both by 
potentiating its ability to block p63 transcriptional activity and by influencing other 
mutant p53 transcriptional functions (Javier E. Girardini et al. 2011). 
  
 
Regulation of mutant p53 protein stability  
Although a drastic difference between the stability of mutant and wt p53 has been 
reported in cancer cells, many aspects of their regulation are shared. The majority of the 
positive and negative regulators of wt p53 have a similar regulatory effect on mutant 
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p53 in normal cells (Terzian et al. 2008; Meek & Anderson 2009; Alsheich-Bartok et al. 
2008). However, the tightly controlled myriad of positive and negative auto-regulatory 
loops, which govern wt p53 levels, is uncoupled to mutant p53 proteins in the context of 
cancer cells.   
 
Regulation of mutant p53 protein degradation  
High levels of mutant p53 are generally found in tumours (Bártek et al. 1991). 
However, mutation by itself is not sufficient to explain the greater stability of mutant 
p53 compared to its wild-type counterpart in cancer cells. Indeed, several murine and 
zebrafish models, that are homozygous for mutant p53, display no stabilization of the 
protein in normal tissues but have high levels in tumours arising in these backgrounds 
(Lang et al. 2004; Lee et al. 2008; Olive et al. 2004). Similarly, mutant p53 does not 
accumulate in normal tissues from patients with Li-Fraumeni syndrome, but only in 
derived tumours (Soussi & Béroud 2001).  
Interestingly, Mdm2–/– mice harboring knock-in TP53 mutants accumulate mutant p53 
also in some normal tissues (Terzian et al. 2008), thus indicating that Mdm2, besides 
acting on wild-type p53, is a pivotal regulator of mutant p53 stability in vivo.  
Despite mutant p53 is susceptible to Mdm2-mediated degradation (Haupt et al. 1997; 
Lukashchuk & Vousden 2007), contrary to wild-type isoform the mutant protein does 
not form a feedback loop with Mdm2, and thus is incapable of inducing the 
transcription of the E3 ubiquitin ligase (Midgley & Lane 1997). Therefore, following 
stress-induced stabilization of wt and mutant p53, only the wtp53 recovers to basal 
levels under the influence of Mdm2. Furthermore, the E3 ubiquitin ligase Mdm2 is able 
to interact with multiple domains of p53, which allows it to bind to both conformational 
p53 mutants as DNA contact (Shimizu et al. 2002; Wallace et al. 2006).  
In vitro biochemical experiments have demonstrated that mutant p53 is a substrate of 
another ubiquitin ligase that targets also wild-type p53: the C-terminus of HSP70- 
interacting protein (CHIP) (Esser et al. 2005; Lukashchuk & Vousden 2007). CHIP- and 
Mdm2-mediated ubiquitylation of mutant p53 is counteracted by the chaperone HSP90, 
which binds to mutant p53 increasing its stability (Esser et al. 2005; Nagata et al. 1999). 
HSP90 is frequently over-activated in tumours (Kamal et al. 2003), thus the dependency 
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of mutant p53 on HSP90 may partly account for its specific accumulation in tumours 
and underlies the therapeutic potential of HSP90 inhibitors (Solit & Rosen 2006).  
Autophagy may also play a role in mutant p53 degradation following proteasomal 
inhibition (Choudhury et al. 2013; Rodriguez et al. 2012). In fact, it has been reported 
that glucose restriction-induced macro-autophagy leads to mutant p53 depletion as 
effect of its de-acetylation and ubiquitination (Rodriguez et al. 2012). Nevertheless, this 
degradation is Mdm2-dependent, but interestingly does not involve the proteasome 
(Morselli et al. 2008; Tasdemir et al. 2008). Additionally, glucose starvation combined 
with confluent growth conditions could promote mutant p53 degradation by a 
specialized form of autophagy known as chaperone-mediated autophagy (CMA) 
(Vakifahmetoglu-Norberg et al. 2013), a mechanism that induce degradation of protein 
through a lysosomal-dependent machinery. In particular, the inhibition of autophagy 
leads to increased cytosolic levels of mutant p53 proteins, which interact with heat 
shock protein Hsc70 which in turn promotes its degradation in a lysosome-dependent 
manner. 
The degradation of mutant p53 can be also induced through the 20S proteasome after 
inhibition of NADH quinone oxidoreductase 1 (NQO1), for example by dicoumarol, in 
an Mdm2-independent manner. Specifically, mutant p53 interacts with NQO1, 
rendering cells resistant to NQO1 inhibitors (Tsvetkov et al. 2010). Consistently, 
NADH quinone oxidoreductase 1  is elevated in many cancers, which may contribute to 
the stabilization of mutant p53 (Belinsky & Jaiswal 1993).  
 
Post-translational modifications of mutant p53 
In response to a variety of stress stimuli, p53 is rapidly stabilized and activated through 
a complex repertoire of post-translational modifications that inhibit its interaction with  
Mdm2 (Kruse & Gu 2009; Vousden & Prives 2009) 
Although the mechanism of hyperstabilizzation of mutant p53 is not completely known 
several evidences showed that, like for wt p53, PTMs in p53 mutant proteins are also 
required for its stabilization and activation . 
Indeed most of the PTMs of wild-type p53, such as phosphorylation and acetylation, are 
non-discriminatory between wt and mutant p53 proteins (Terzian et al. 2008; Meek & 
Anderson 2009; Alsheich-Bartok et al. 2008) and contribute to mutant p53 stability 
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protecting it from degradation by Mdm2. 
Interestingly, the phosphorylation on Ser15, which has major role in the control of DNA 
damage-induced p53 stabilization, is also induced on mutant p53 in response to 
genotoxic stress (i.e. camptothecin) (Dun Li et al. 2011; Alsheich-Bartok et al. 2008).  
In particular, it was found that mutant p53, expressed in UV induced primary mouse 
skin tumours and in cell lines established from primary tumours, is constitutively 
phosphorylated on Ser15, inducing mutant p53 protein stabilization and its 
accumulation in cell nuclei. Constitutive phosphorylation of mutant p53 at Ser15 is 
mediated by ERK1/2 MAP kinase (mitogen-activated protein kinase), which physically 
interacts with mutant p53 in the nucleus (Melnikova et al. 2003). 
Another important PTM to stabilize p53 protein is acetylation. Although mutant p53 is 
known to be acetylated (Perez et al. 2010), the roles of these acetylations on mutant p53 
still need further investigation. It has been unveiled that the activation of surtuins 
(SIRTs), an evolutionally conserved enzyme family acting as protein deacetylases/ADP 
ribosyltransferases, induces wt and mutant p53 deacetylation on Lys382 residue, 
leading to reduction of their stability in TNBC cell lines. This evidence revealed an 
important role of acetylation in controlling the stability of mutant p53 proteins (Yi et al. 
2013; Z. Y. Zhang et al. 2015).  
In addition to mutant p53 itself, modifications of Mdm2/ MdmX contribute to the 
protection of mutant p53 from these key inhibitors. In response to DNA damage, ATM 
and c-Abl phosphorylate Mdm2 and MDMX compromising their ability to degrade p53 
(Maya et al. 2001; Goldberg et al. 2002; Cheng et al. 2009). 
  
 
Mutant p53 addiction 
Several evidence have observed that mutant p53 proteins exhibit GOF activities 
(Dittmer et al., 1993), and accumulating studies unveiled that knockdown of mutant p53 
in cancer cells attenuates their malignant properties, suggesting that their oncogenic 
potential is dependent on the presence of high mutant p53 protein levels. 
Experiments in several cancer cell lines expressing mutant p53 and implanted in nude 
mice showed that the depletion of p53 mutant protein using either stable or conditional 
shRNA-mediated knockdown, rendered those cells significantly less tumourigenic by 
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compromising mutant p53 GOF activities (Bossi et al. 2006; Bossi et al. 2008). In 
agreement with the impact of mutant p53 on the response to genotoxic anticancer drugs 
in vitro, the knockdown of mutant p53 sensitized several cancer cells to 
chemotherapeutic agents such as doxorubicin, etoposide, and cisplatin, inducing a 
higher apoptotic response. These results confirmed the existence of GOF activity of 
some human tumour-derived p53 mutants (Bossi et al.,2006). Remarkably, constitutive 
inhibition of mutant p53 reduced tumour growth in nude mice and showed reduced 
stromal invasion and angiogenesis, suggesting a positive role of mutant p53 in the 
regulation of this process (Bossi et al. 2008). Furthermore, it has been reported that 
knockdown of mutant p53 in human triple negative breast cancer cell lines did not alter 
primary tumour growth, but strongly reduced metastasis to both lymph nodes and lung 
(Adorno, Cordenonsi, Montagner, Dupont, Wong, Hann, Solari, Bobisse, Rondina, 
Guzzardo, Anna R. Parenti, et al. 2009).  
Nonmalignant breast epithelial cells in 3D cultures form spheroids reminiscent of acinar 
structures found in vivo, whereas breast cancer cells display highly disorganized 
morphology. Prives and colleagues showed that mutant p53 depletion in breast cancer 
cell lines (MDA-MB-231cells and in MDA-MB-468) grown in 3D cultures is sufficient 
to phenotypically revert breast cancer cells to a more acinar-like morphology (Freed-
Pastor et al. 2012). Inhibition of mutant p53 by siRNA significantly reduced the 
transcriptional activity of the SREBPs transcription factors leading to a strong reduction 
of the expression of multiple enzymes involved in the mevalonate pathway and 
consequent inhibition of YAP/TAZ transcriptional activity (Sorrentino et al. 2014) 
(Freed-Pastor et al. 2012).  
More recently, Moll and colleagues using a novel mutant p53 mouse model expressing 
an inactivatable p53R248Q hotspot mutation, showed that tumours depend on sustained 
mutant p53 expression. In particular tamoxifen-induced mutant p53 ablation reduced 
tumour growth and extended the survival of host mice. Importantly, clinically advanced 
tumours responded to mutant p53 ablation with regression or stagnation due to marked 
tumour apoptosis. (Alexandrova et al. 2015).  
 
Pharmacological strategy targeting mutant p53 
A number of evidence reveals that stabilization of mutant p53 proteins in tumours is 
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required for its GOF properties, while its reduction mitigates the malignant potential of 
cancer cells, hence targeting mutant p53 represents an attractive strategy for cancer 
therapy. In these years several small-molecule compounds, that specifically target 
mutant p53 have been identified and are now in preclinical or clinical development. 
According to the mechanism of how these compounds target mutant p53 proteins they 
can be divided in several groups (Figure 7). 
 
 
 
-Compound that restore wild-type p53 activity 
Recent studies clearly demonstrated that restoration of wt p53 activity is able to 
interfere with tumour progression in vivo: the re-introduction of p53 in tumours lacking 
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Fig. 2. Potential mutant p53-based therapeutic strategies. (1) Inducing mutant p53 degradation: disruption of stable complexes between mutant p53 and the HSP90 machinery
by  17AAG (HSP90 inhibitor) or SAHA (HDAC6 inhibitor) may  release MDM2 and CHIP E3 ubiquitin ligases from inhibition. Mutant p53 degradation may  also be enhanced by
glucose  restriction; (2) Inhibiting mutant p53 activation: pharmacological inhibition of kinases or mutant p53 activators as Pin1 may  restrain its pro-oncogenic activities by
avoiding  proper activation; (3) Inhibiting mutant p53 activities: mutant p53 functions may be restrained by avoiding the interaction with partners or interfering with the
functional significance of mutant p53 complexes; (4) Combined strategies: using simultaneously drugs that target mutant p53 and inhibitors of pathways that cooperate
with  its malignant functions may  synergize to hinder tumor progression; (5) Reactivating wt  (wild type) functions: pharmacological reactivation of wt-like functions in p53
point  mutants may recover tumor suppressor capabilities specifically in tumor cells. TFs (transcription factors); TRKs (tyrosine kinase receptors).
shown to be inactivated by recruitment into the same complexes
[26]. Disruption of this complex or inhibition of chaperone activity
in cultured cells released both E3 ubiquitin ligases from inhibi-
tion and triggered mutant p53 degradation [26,41]. On this basis
the design of pharmacological strategies aimed at inducing selec-
tive degradation of mutant p53 through inhibition of HSP90 were
suggested. Pharmacological inhibition of HSP90 ATP-dependent
chaperone activity by Geldanamycin or 17AAG is able to reduce
mutant p53 stability [24,26] (Fig. 2). Several HSP90 inhibitors
were shown to inhibit tumor growth in pre-clinical models and in
patients, and some of them are in phase II clinical trials [42]. How-
ever for most of them the effect usually disappears when treatment
is stopped, in line with the idea that HSP90 should exert a gen-
eral effect in alleviating proteotoxic stress. It would be interesting
to analyze whether if this inhibitors may  have more strong and
permanent effects in mutant p53 bearing tumors considering the
specific effect of HSP90 on mutant p53 stability.
Histone deacetylase inhibitors (HDACi) provided another exam-
ple on how to overcome the hyperstability of mutant p53 in tumor
cells. HDACi are being intensively studied as promising chemother-
apy drugs since they elicit different anticancer responses with a
remarkable specificity for tumor cells, and some of them are under-
going clinical trials [43]. At least three HDACi have been reported
to reduce mutant p53 levels in cell lines, FR901228, Trichostatin
A (TSA) [23] and suberoylanilide hydroxamic acid (SAHA) [25],
which however were proposed to act through different mecha-
nisms. SAHA inhibits HDAC6, which normally activates HSP90 by
promoting deacetylation of K294 (Fig. 2). Upon SAHA treatment,
MDM2  and CHIP may  be released from inhibition by HSP90 com-
plex and induce mutant p53 degradation [25]. Nevertheless, an
inhibitory effect of HDAC inhibitors on transcription of TP53 was
described, that may  also cooperate with the observed effects [44].
In the case of FR901228 and TSA, even if they may  counteract HSP90
activity at rather high concentrations, the effect on mutant p53 lev-
els was  observed at lower concentrations and was accompanied by
transcriptional induction of p21 and MDM2  and conformational
changes in mutant p53, suggestive of reactivation of wt-like con-
formation [23].
Further contributing to delineate the mechanisms of mutant p53
regulation, it was  shown that phosphorylation of mutant p53 on
S15 and S37 contributes to protein stabilization [45]. The kinase
responsible for these modifications is DNA-PK, which is also able
Figure 7. potential mutant 53-based therape tics str tegies. (1) Inducing mutant p53 
degradation: disruption of stable com lex betwee  mutant p53 nd Hsp90 machinery by 
17AAG (HS90 inhibitor) or SAHA (HDAC6 inhibitor) ma  relea e MDM2 and CHIP E3 
ubiquitin ligases from inhibiti n. M tant p53 degradation may also be enhanced by glucose 
restriction; (2) In ibiting mut nt p53 activation: pharmacological inhibition of kinases or 
mutant p53 activators as Pin1 may restrain its pro-oncogen c activities by avoiding proper 
activation. (3) Inhibiting mutant p53 activities: mut t p53 functions may b  restrained by 
avoiding the interaction with partners or interfering with the functional significance of 
mutant p53 complexes; (4) Combined strategies: using simulta eously drugs that target 
mutant p53 and inhibitors of pathway that cooperate with its malignant functions may 
synergize to hinder tumour progression; (5) Reactivating wt (wild type) functions: 
pharmacological reactivation of wt-like functions in p53point mutants may recover tumour 
suppressor capabilities specifically in tumour cells. TFs(transcription factors); TRKs 
(tyrosine kinase receptors) (Girardini et al. 2014). 
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p53 expression triggered a fast and massive regression of established tumours caused by 
induction of p53-dependent apoptosis or senescence (Martins et al., 2006; Ventura et 
al., 2007; Xue et al., 2007). These observations suggest that p53 restoration would be 
effective in tumour therapy and boost the search for new strategies to activate the p53 
pathway in tumours. In the last years, several approaches have been proposed to 
increase the wt p53 stability and activity with peptides, natural compounds or small 
molecules, and to restore the wild-type properties of p53 mutants in cancer cells (Brown 
et al., 2009; Grinkevich et al., 2009; Issaeva et al., 2004; Lain et al., 2008; Vassilev et 
al., 2004) (Figure 5). 
The evidence that suggest that functional reactivation of p53 can be restored from 
mutant p53 are: (1) many p53 mutants are temperature sensitive and restore the p53 
activity at the permissive temperature (Zhang et al. 1994; Selivanova et al. 1998); (2) 
synthetic peptides, derived from C-terminal domain of p53, restore the sequence-
specific DNA binding and transcriptional activity of p53 (Friedler et al. 2002; 
Selivanova et al. 1997) and (3) insertion of second-site mutations or a N-terminal 
deletion in several p53 mutants restore the p53 transcriptional activities (Nikolova et al. 
2000; Bykov, Issaeva, Shilov, et al. 2002; Liu et al. 2001).  
Recently, attempts have been made to identify small molecules that reactivate mutant 
p53 (Table1). 
 
CP-31398 and STIMA-1 (SH Group-Targeting Compound That Induces Massive 
Apoptosis) 
The first p53-reactivating compound, CP-31398 (styrylquinazoline), was identified 
through a structure-based screening as a compound that stabilize the wild type p53 and 
enhances its transcriptional activities in cells (Wang et al. 2003). CP-31398 promotes 
mitochondrial translocation of p53, leading to changes in mitochondrial membrane 
permeability pore transition (MPT) and consequent cytochrome c release in human skin 
carcinoma cells expressing mutant p53 (Tang et al. 2007). However, a recent study 
reported that CP-31398 causes toxicity in liver and other tissues in animal models, 
suggesting the necessity to modify the structure of CP-31398 to reduce its toxicity 
(Johnson et al. 2011). 
STIMA-1 [2-vinylquinazolin-4-(3H)-one] is a low molecular weight compound that was 
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identified as one of the CP-31398 derivatives, which induced mutant p53 (p53R175H and 
p53R273H)-dependent growth suppression. STIMA-1 was showed to stimulate mutant 
p53 binding to DNA, in vitro, and to induce expression of p53 target proteins (p21, 
PUMA, and BAX ), triggering apoptosis in mutant p53-expressing human tumour cells. 
Mechanistically, both CP-31398 and STIMA-1 bind to the cysteine residues in the core 
domain of mutant p53, leading to stabilization of wild-type p53 conformation and 
subsequent restoration of transcriptional activity (Zache, Lambert, Rökaeus, et al. 
2008).  
 
PRIMA-1 and PRIMA-1MET 
PRIMA-1 [2,2-bis (hydroxymethyl)-3-quinuclidinone] and its methylated analog 
PRIMA-1MET are molecules that can restore sequence-specific DNA binding and 
convert mutant p53 conformation to wild-type, thereby leading to the transactivation of 
p53 target genes (Bykov, Issaeva, Selivanova, et al. 2002; Bykov, Issaeva, Shilov, et al. 
2002; V. J. Bykov et al. 2005). 
PRIMA-1 was first identified through a screening as a compound that suppressed 
proliferation of osteosarcoma cell line expressing p53R273H with little effect on the 
parental cells. In particular PRIMA-1 and PRIMA-1MET were unveiled as compounds 
capable of inducing apoptosis in human tumour cells through restoration of the 
transcriptional transactivation function to mutant p53 cells (Bykov, Issaeva, Shilov, et 
al. 2002; V. J. Bykov et al. 2005). Interestingly, it has been also reported that mutant 
p53 reactivating compound PRIMA-1MET acts synergistically with several 
chemotherapeutic drugs, such as cisplatin, to induce tumour cell apoptosis and to inhibit 
human tumour xenograft growth in vivo (V. J. N. Bykov et al. 2005). The molecular 
mechanism by which PRIMA-1 and PRIMA-1MET lead to refolding of mutant p53 (both 
DNA contact and structural mutants isoforms) involves the conversion of these 
compounds to products which form adducts with thiol groups in the mutant p53 core 
domain, leading to restoration of wild-type conformation and induction of apoptosis in 
tumour cells (Lambert et al. 2009; Lambert et al. 2010). Several studies have 
successfully validated their tumour suppressive effects in mouse models of multiple 
types of cancer (Rao et al. 2013; Zache, Lambert, Wiman, et al. 2008) and importantly, 
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the PRIMA-1MET is currently in phase I of clinical trials in liver or prostate cancer 
patients (Farnebo et al. 2010). 
 
MIRA-1 and its structure analogs  
Using the same screening strategy as PRIMA-1, MIRA-1 (NSC19630) was identified as 
a compound that suppressed proliferation of osteosarcoma cell lines expressing p53R273H 
(V. J. Bykov et al. 2005). MIRA-1 and its structural analogs (MIRA-2 and MIRA-3) 
were showed to inhibit proliferation and also to induce cell death in cancer cells 
expressing mutant p53 (V. J. Bykov et al. 2005)and in mouse models. 
In particular, MIRA-1 restores native wild-type p53 conformation, leading to enhanced 
DNA-binding activity of mutant p53 (p53R175H and p53R248Q) and increased expression 
of p53 downstream target genes (Mdm2 and p21) in several mutant p53-carrying cancer 
cell lines.  
 
RITA (NSC6522887) 
RITA (reactivation of p53 and induction of tumour cell apoptosis) was identified 
through cell proliferation assay-based screening as a compound that suppresses the 
growth of cancer cell lines expressing wild-type p53 with minimum effect on p53-null 
cells. 
Initially, RITA was found to induce expression of p53 target genes and massive 
apoptosis in several tumour cells lines expressing wild-type p53 and to suppress the 
growth of human fibroblasts and lymphoblasts only upon oncogene expression and 
showed substantial p53-dependent antitumour effect in vivo (Issaeva et al. 2004; 
Nieves-Neira et al. 1999). Mechanistically, RITA disrupts the p53-Mdm2 complex by 
binding to p53 (Issaeva et al. 2004) and induces HIPK2 (proapoptotic homeodomain-
interacting protein kinase-2) stabilization with consequent phosphorylation of p53 on 
Ser46 (Rinaldo et al. 2009). Subsequent prolyl-isomerization by Pin1 of the Ser46-
Pro47, leads to decreased polyubiquitination of p53 in favor of its monoubiquitination, 
with consequent relocalization of cytosolic p53 to mitochondria to induce p53 
transcription-independent apoptosis (Sorrentino et al. 2013). 
Later, RITA was found to suppress also the growth of cancer cell lines carrying various 
p53 mutants (p53R175H, p53R213Q/Y234H, p53R248W, p53R248Q, p53I254D, p53R273H, and 
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p53R280K) by restoration of p53 transcriptional activity (p21, NOXA, PUMA, and 
GADD45) and induction of apoptosis through upregulation of pro-apoptotic proteins 
and downregulation of several oncogenes or anti-apoptotic proteins (Zhao et al. 2010; 
Burmakin et al. 2013; Grinkevich et al. 2009). However, the exact mechanism by which 
RITA activates both wild type and mutant p53 to induce apoptosis remains unclear.  
 
NUTLIN-3a 
Nutlin is a potent and selective pharmacological Mdm2 inhibitor that prevents Mdm2-
p53 interaction inducing wild-type p53 activation, and it is currently being tested in 
phase 1 clinical trail (Vassilev et al. 2004) 
It was unveiled that nutlin competitively binds to Mdm2 in the p53-binding pocket 
within the N-terminus of Mdm2, thereby leading the activation and stabilization of p53 
in cancer cells, without causing major conformational changes in the Mdm2 molecule 
and preserving its E3-ligase activity (Vassilev et al. 2004). As a consequence of the 
reactivation of wild-type p53 induced by Nutlin-3a, the tumour suppressor p53 was 
showed to induce cell cycle arrest, apoptosis and growth inhibition in human cancer 
cells harboring wild-type p53, but not mutant p53, and in tumour xenograft in nude 
mice (Vassilev et al. 2004; Tovar et al. 2006; Xia et al. 2008). 
Although the apoptotic effects of Nutlin-3a have been initially linked exclusively to the 
transcriptional activities of p53 in the nucleus (Vassilev et al. 2004), it has recently 
emerged how the transcription-independent activity of p53 could be a major contributor 
to the apoptosis induced by this drug in human cancer cell lines. Indeed, Vaseva and 
others found that p53 rapidly translocates to the mitochondria after treatment of cells 
with Nutlin-3a, and activates a pro-apoptotic signal that is strongly independent from its 
transcriptional activities (Vaseva et al. 2009; Steele et al. 2008). 
Mechanistically, the Mdm2-p53 complexes are only partially disrupted by Nutlin and 
the remaining low levels of complex formation between Mdm2 and p53 are sufficient 
for mediating p53 moubiquitination which is known to promote p53 trafficking to 
mitochondria (Vaseva et al. 2009). 
 
	 36	
NSC319726/ZMC1 (Zinc Metallochaperone-1)  
Zinc is required for proper folding of p53 protein, while lack of zinc in the central core 
domain of p53 leads to its unfolding (Bykov, Issaeva, Shilov, et al. 2002; Margalit et al. 
2012; Pintus et al. 2013). Several evidence reported that administration of zinc, in 
combination with Adriamycin, restore activity of misfolded p53 and enables induction 
of its proapoptotic and tumour suppressor functions in vitro and in vivo. Indeed, 
NSC319726 [zinc metallochaperone-1 (ZMC1)], a thiosemicarbazone derivative, was 
identified in a screen of the NCI60 panel of human tumour cell lines, as a compound 
able to facilitate the binding of mutant p53 to zinc, exhibiting selective toxicity to cells 
carrying p53R175H with minimum effects on cells expressing wild-type p53 and other 
p53 mutants (p53R248Q and p53R273H) (Yu et al. 2012).   
 
Chetomin 
Chemotin (CTM) is a small-molecule that reactivates mutant p53 and restores the WT-
like function, through the p53-heat-shock protein 40 (Hsp40) axis (Hiraki et al. 2015). 
The chemotin was identified trough a high-throughput chemical library screening using 
a luciferase reporter with the p53 response element promoter in p53-null cells carrying 
mutant p53, as a compound that increased luciferase activity. In particular, CTM was 
found to induce p53 target genes (p21, PUMA, and Mdm2) and showed anticancer 
effects in p53 R175H specific manner in vitro and in vivo (Hiraki et al. 2015) 
Mechanistically, Chemotin does not bind directly to mutant p53 R175H protein, but was 
found that CTM binds to Hsp40 and increases the binding capacity of Hsp40 to the 
p53R175H mutant protein, causing a potential conformational change to a wild-type-like 
p53 (Hiraki et al. 2015). 
 
Other Compound that restore wild-type p53 activity 
Several other small molecules have been reported as mutant p53 reactivators.  
-Stictic acid (Wassman et al. 2013) was identified through an ensemble-based virtual 
screening approach, and its mechanism of p53 reactivation is through docking of the 
small molecule in the open L1/S3 p53 binding pocket around Cys124, Cys135, and 
Cys141 (Wassman et al. 2013). 
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-The p53 reactivator (P53R3) restores sequence-specific DNA binding of several p53 
mutants (p53R175H, p53M237I, and p53R273H) and induces p53-dependent anti- 
proliferative effects in mutant p53 cancer cells with increase in mRNA expression of 
many p53 target genes (p21,GADD45, BAX,PUMA) but also in wild type p53 cancer 
cells  (Weinmann et al. 2008). 
-SCH529074 was identified by a DNA-binding assay-based screening as a compound 
that enabled p53R273H to bind to a consensus p53 DNA-binding site . The small 
molecule SCH529074, acting as a chaperone, binds specifically to the p53 DBD 
restoring DNA binding activity to mutant p53 and inhibits HDM2-mediated 
ubiquitination (Demma et al. 2010). 
-WR1065 is an aminothiol used to protect tissues against the damaging effects of 
radiation and chemotherapeutic drugs. WR1065 has been shown to induce wild-
type p53 accumulation and activation in cultured cells, suggesting a role of p53 in 
cytoprotection. WR-1065 was showed to increas wild-type p53 activity through a JNK-
dependent signaling pathway, but not through genotoxic mechanisms (Shen et al. 2001; 
Pluquet, North, Bhoumik, et al. 2003; Pluquet, North, Richard, et al. 2003). 
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Peptides and Aptamers 
The equilibrium between the properly folded and misfolded states of p53 may be 
affected by molecules that interact with p53, stabilizing its native folding and restoring 
wild type p53 activity to cancer cells such as peptides and aptamers (Guida et al. 2008) 
(Tal et al. 2016). 
TABLE 1 | Compounds that induce reactivation of mutant p53.
Compound Type of mutant Mechanism Reference Structure
CP-31398 V173A, S241F, 
R249S, R273H
Stabilize the DNA-binding core domain and induce 
conformational change
(17, 25–27)
STIMA-1, structural 
similarity to CP-31398
R175H, R273H Bind to the cysteine residues in the core domain and stabilize 
wild-type p53 conformation
(28)
PRIMA-1 and the 
methylated analog 
(APR-246/PRIMA-1MET)
R175H, R273H Bind to thiol groups in the core domain and restore wild-type 
conformation
(23, 29, 30)
MIRA-1 (NSC19630), 
and its analogs MIRA-2 
and -3
R175H, R248Q, 
R273H
Prevent unfolding of wild-type and mutant p53 and restore 
native wild-type p53 conformation
(31)
RITA (NSC652287) R175H, R248W, 
R273H, R280K
Restore p53 transcriptional activity and induce apoptosis (32, 33)
NSC319726/
ZMC 1 (zinc 
metallochaperone-1)
R175H, R172H 
(mouse)
Restore wild-type p53 conformation and activity with  
MDM2-dependent degradation
(34–36)
Chetomin (CTM) R175H Increase Hsp40 (DNAJB1) levels and Hsp40-p53R175H binding, 
restoring wild-type p53 conformation, activity, and MDM2-
dependent degradation
(37)
PK7088 Y220C Bind to a p53Y220C-specific surface cavity and stabilize p53Y220C 
with restored wild-type p53 conformation
(38)
Stictic acid (NSC87511) R175H, G245S Target cysteine 124 at the p53 core domain and restore  
wild-type p53 activity
(39)
p53R3 R175H, M237I, 
R273H
Restore sequence-specific DNA binding and p53 
transcriptional activities
(40)
SCH529074 R175H, L194F, 
R248W, R249S, 
R273H
Restore sequence-specific DNA binding and p53 
transcriptional activities
(41)
WR-1065 V272M Restore DNA binding and transcriptional activities of p53V272M (42–45)
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PRIMA-1 and its methylated analog PRIMA-1MET (also known 
as APR-246) not only enhance stability of wild-type p53 at 37°C, 
but also induce conformational change of p53R175H, leading to 
restoration of DNA-binding activity of p53R175H with increased 
MDM2 and p21 mRNA expression (23). Notably, PRIMA-1 
refolds previously accumulated unfolded mutant p53 (23). The 
(Parrales	&	Iwakuma	2015) 
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Peptides libraries have proved a useful approach to identify drugs that specifically target 
mutant p53 but not wild-type form to restore p53 activity. 
-Peptide aptamers (PA) 
Peptide aptamers are combinatorial protein molecules with specific bind affinity to 
given target proteins under intracellular conditions. The typical structure of peptide 
aptamers is a short peptide region inserted within a scaffold protein. The 
short peptide region is responsible for binding with its target protein and the scaffold 
protein helps to enhance the binding affinity and specificity through restriction on the 
conformation of the binding-peptide (J. Li et al. 2011). 
Using the yeast two-hybrid method and molecular modeling analysis, the peptides 
aptamers have been identified able to interact with both p53 conformational mutants 
(p53R175H, p53D281G) and contact mutants (R273H, R248W) but not wild-type p53 
(Guida et al. 2008).  
Moreover, PAs were showed to break also the complexes between the mutant p53 and 
p63/, p73 and the respective isoform proteins, increasing in this way the free p73 and 
p63 and restoring the oncosuppressoiver activity of these proteins (Guida et al. 2008). 
In tumour cells expressing mutant p53, but not in cells harboring wt p53 or in p53-null 
cells, PAs were observed to trigger apoptosis while the ablation of endogenous mutant 
p53 reduced PA-induced cell death, further suggesting that the induction of apoptosis 
depends on the presence of mutant p53. Interestingly, the apoptotic response induced by 
PAs was comparable with that exerted by PRIMA-1 (Guida et al. 2008). 
- p53 conformation activating peptides (pCAPs) 
Very recently, Tal P., et al., (Tal et al. 2016) have described an innovative approach for 
the identification of mutation p53 reactivating peptides through functional screening of 
phage display libraries. Through a phage display technology, based on the interactions 
between mutant p53 and random peptide libraries presented on phages and enriched for 
phage that favor the correctly folded p53 conformation, they obtained a large database 
of potential reactivating peptides. A total of close to 350 peptides, deduced from the 
phage sequences and known as pCAPs (p53 conformation activating peptides), were 
synthesized and subjected to several alternative complementary methods of semi high-
throughput functional screening. Analyzing the ability of these peptides to induce p53 
transcriptional activity, several candidate lead peptides (pCAP-24R, pCAP-54, pCAP-
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60R, pCAP-97R) were found to increase the expression of p53 target genes. 
Importantly, lead peptides elicited dramatic regression of aggressive tumours in mouse 
xenograft models (Tal et al. 2016). 
 
-Compounds that deplete mutant p53 
Although many p53-reactivating compounds seem to target more than one p53 mutant, 
it remains unclear if these can reactivate all p53 mutants or specific mutant proteins. 
Another important strategy to target oncogenic p53 is to use compounds that induce 
mutant p53 degradation without altering wild-type p53. These classes of molecules can 
be used as effective therapeutic strategies for both cancers carrying only mutant p53 and 
those retain a heterozygous status. Moreover, these compounds may be valuable, for 
elucidating the mechanisms of stabilization or of mutant p53 in cancer cells (Figure 5) 
(Table 2). 
 
Hsp90 inhibitors: Geldanamycin, 17-AAG, Ganetespib 
The heat shock protein 90 (Hsp90) signaling pathway is ubiquitously upregulated in 
cancer cells where plays an important role in stabilizing mutant p53 by protecting it 
from both CHIP and Mdm2-mediate ubiquitination and degradation (Wang & Chen 
2003; Dun Li et al. 2011). 17-AAG (17-allylamino-17-demethoxygeldanamycin) is a 
potent and highly specific Hsp90 inhibitor currently in phase I to III clinical trials for 
refractory multiple myeloma and several solid cancers including breast cancer (Trepel et 
al. 2010; Dun Li et al. 2011). It has been reported that 17AAG specifically induces the 
release of mutant p53 from hsp90, promoting degradation of varieties of p53 mutants 
(p53R175H, p53L194F, p53R273H, and p53R280K) and reducing cell viability (Dun Li et al. 
2011). 
Ganestespib, another Hsp90 inhibitor, is 50-fold more potent than 17-AAG in 
destabilizing mutant p53 with little effect on wild-type p53 levels which induces mutant 
p53 depletion with increased apoptosis in tumours in vivo (Dun Li et al. 2011). 
 
Histone Deacetylase inhibitors: vorinostat/ SAHA, Romidepsin/Depsipeptide  
Histone deacetylase (HDAC) inhibitors (HDACi) are a new class of promising anti-
cancer drugs to compromise mutant p53 protein stabilization.  
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SAHA (suberoylanilide hydroxamic acid) also know as Vorinostat is the only FDA-
approved HDACi that acts by inhibiting HDAC6, a positive regulator of Hsp90, 
disturbing the physically interaction of HDAC6/Hsp90/mutant p53 complex, leading to 
mutant p53 ubiquitination by Mdm2 and CHIP and degradation (D Li et al. 2011; 
Marks 2007). In particular, it was unveiled that SAHA exhibits preferential cytotoxicity 
in mutant p53 tumour cells, whereas wtp53 and p53 null tumour cells are much less 
sensitive (D Li et al. 2011). The cytotoxicity of SAHA in mutant p53 cancer cells, 
despite being pleiotropic drug, is largely due to the destabilization of mutant p53 protein 
via Hsp90/HDAC6 inhibition. The mutant p53 destabilization induced by SAHA is at 
least as efficiently as 17AAG, but a synergistic effect of both drugs was showed to be 
correlate with further mutant p53 degradation in some mutant p53 breast-cancer cells 
lines (D Li et al. 2011; Alexandrova et al. 2015). This synergistic cytotoxicity could be 
explain that the inhibition of HDAC6 by SAHA, that in turn causes hyperacetylation of 
HSP90, further lowers the threshold of inhibiting HSP90 by 17AAG, resulting in 
enhanced ubiquitination of HSP90 client proteins including mutant p53.  
Moreover pharmacological degradation of mutant p53 via HSP90 targeting by SAHA it 
was showed also mediate chemosensitization in response to conventional genotoxic 
drugs such as topoisomerase inhibitor camptothecin (Alexandrova et al. 2015). 
 
Arsenic Compounds 
Arsenic trioxide (ATO), a drug for patients with acute promyelocytic leukemia, is found 
to target and degrade a class of proteins with high levels of cysteine residues and vicinal 
thiol groups, such as promyelocytic leukemia protein (PML) and PML-retinoic acid 
receptor α fusion protein (Beauchamp & Üren 2012). 
Some evidence revealed that wild type p53 is induced by arsenic trioxide in tumour 
cells, presumably due to arsenic-induced oxidative stresses(Jiang et al. 2010). In 
addition, Yan et al., unveiled that arsenic compounds target mutant p53 for degradation 
and inhibit the proliferation of tumour cells harboring a mutant p53. In particular, ATO 
induces proteasomal-dependent degradation of several mutants p53 proteins (p53R175H, 
p53H179Y/R282W, p53R248W, and p53R273H) and also increases E3 ubiquitin ligase Pirh2 
expression, leading to ubiquitination and degradation of several mutant p53 (Yan et al. 
2014). However, it should be noted that arsenic compounds have carcinogenic effects 
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and are known to induce several types of cancer (Hughes et al. 2011).  
 
Disulfiram 
Disulfiram (DSF) is a FDA approved drug for the treatment of alcoholism and available 
for clinical use since over 5 decades for some types of cancer including glioblastoma 
multiforme and metastatic non-small cell lung cancer (Kona et al. 2011; Nechushtan et 
al. 2015). Paranjpe et al. (Paranjpe 2013) reported that DSF induced degradation of both 
wild-type p53 and p53R273H through the 26S proteasome pathway (Paranjpe 2013). 
 
Spautin 
The small molecule Spautin is a derivative of MBCQ (4-((3,4-methylenedioxyben- 
zyl)amino)-6-chloroquinazoline)  and an inhibitor of autophagy. 
Spautin-1 promotes the degradation of Vps34 PI3 kinase complexes by inhibiting two 
ubiquitin-specific peptidases, USP10 and USP13. Since USP10 also deubiquitinates 
wild-type p53, Spautin-1 promotes the degradation of wild-type p53 (Liu et al. 2011; 
Yuan et al. 2010). Moreover, suppression of macroautophagy by Spautin-1 under 
glucose-free and confluent conditions was found to induce degradation of several p53 
mutants (p53R158InF, p53R175H, p53R248Q, p53S241F, p53G266E, p53R280L, and p53R273H) 
through the chaperone-mediated autophagy (CMA) pathway (Vakifahmetoglu-Norberg 
et al. 2013). Mutant p53 degradation induced by Spautin-1 is dependent on nuclear 
export of mutant p53 and independent of Mdm2 and the ubiquitin proteasome pathway 
(Vakifahmetoglu-Norberg et al. 2013; Vakifahmetoglu-Norberg & Yuan 2013) 	
Other compounds that deplete mutant p53 
Several other small molecules have been reported to induce mutant p53 destabilization 
and degradation. 
-Gambogic Acid (GA) was showed to reduce viability of mutant p53-expressing cancer 
cells and to increase cytotoxic effects of several chemotherapy drugs in human breast 
cancer cell lines  (Wang et al. 2011) GA prevents the mutant p53-Hsp90 interaction and 
induces mutant p53 nuclear exports and subsequent degradation by CHIP ubiquitin 
ligase (Wang et al. 2011). 
-YK-3-237 was found to inhibit the proliferation of breast cancer cell lines carrying both 
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mutant and wild-type p53. YK-3-237 also decreased the levels of mutant p53 proteins 
(p53V157F, p53M237I, p53R249S, p53R273H, and p53R280K) through reduction in acetylation at 
lysine 382 (K382) of mutant p53, a target site of a NAD+-dependent protein deacetylase 
SIRT1 (also known as sirtuin 1) (Yi et al. 2013). Indeed YK-3-237 activates SIRT1 
enzyme activity (Yi et al. 2013). 
-NSC59984 induces degradation of several p53 mutants (p53R175L, p53R175H, p53S241F, 
and p53R273H/P309S) through Mdm2-mediated ubiquitination (S. Zhang et al. 2015). 
 
 	
TABLE 2 | Compounds that deplete mutant p53.
Compound Type of mutant Mechanism Reference Structure
Hsp90 inhibitors: 17-AAG, 
geldanamycin, ganetespib
R175H, L194F, R248Q, R273H, 
R280K, R172H (mouse)
Reverse the Hsp90’s function to inactivate 
MDM2 and CHIP
(13, 66–69)
HDAC inhibitors: vorinostat/
SAHA, romidepsin/
depsipeptide
R175H, R280K, V247F/P223L Inhibit HDAC6 and disrupt the HDAC6/
Hsp90/mutant p53 complex
(70–72)
Arsenic compounds R175H, R248W, H179Y/R282W, 
R273H
Increase transcripts of Pirh2 and induce 
degradation of mutant p53
(73, 74)
Gambogic acid R175H, G266E, R273H, R280K Inhibit the mutant p53-Hsp90 complex and 
induce CHIP-dependent degradation
(75)
Spautin-1 R158lnF, R175H, S241F, R248Q, 
G266Q, R280L, R273H
Induce mutant p53 degradation via the CMA 
pathway activated by the suppression of 
macroautophagy under glucose-free and 
confluent conditions
(76, 77)
YK-3-237 V157F, M237I, R249S, R273H, 
R280K
Decrease mutant p53 levels through 
deacetylation at lysine 382 by activating 
SIRT1
(78)
NSC59984 R175L, R175H, S241F, R273H/
P309F
Induce MDM2-mediated mutant p53 
degradation and activate p73
(79)
Disulfiram (DSF) R273H Induce degradation of both wild-type p53 and 
p53R273H via the 26S proteasome pathway
(80)
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Arsenic Compounds
Arsenic trioxide (ATO), which is used to treat patients with 
acute promyelocytic leukemia (APL), binds to thiol groups in 
cysteine residues and induces degradation of proteins, such as 
promyelocytic leukemia protein (PML) and PML-retinoic acid 
receptor α (PML-RARα) fusion protein (85). It also activates 
wild-type p53 and upregulates p53 downstream target genes 
with induction of apoptosis (86). Yan et al. (73) asked the pos-
sibility of using arsenic compounds to target mutant p53 for 
degradation and found that ATO or sodium arsenite induced 
proteasomal-dependent degradation of several p53 mutants 
(p53R175H, p53H179Y/R282W, p53R248W, and p53R273H). ATO also 
increases transcripts of an E3 ubiquitin ligase Pirh2, leading 
to ubiquitination and degradation of several mutant p53 (74). 
However, it should be noted that arsenic compounds have 
carcinogenic effects and are known to induce several types of 
cancer (87).
Gambogic Acid
Gambogic acid (GA), a natural product derived from Garcinia 
hanburyi tree, induces apoptosis and inhibits tumor growth 
in vivo by upregulating wild-type p53 at protein levels (88). On the 
other hand, GA induces nuclear exports of mutant p53 (p53R175H, 
p53G266E, p53R273H, and p53R280K) for degradation by CHIP ubiq-
uitin ligase (75). GA prevents the mutant p53-Hsp90 complex 
formation but enhances the mutant p53-Hsp70 interaction (75). 
Biologically, GA reduces viability of mutant p53-expressing 
cancer cells and also increases cytotoxic effects of several 
(Parrales	&	Iwakuma	2015) 
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-Compounds that affect downstream targets of mutant p53  
Another approach to target oncogenic activity of mutant p53 is to reactivate tumour 
suppressive pathways that are inhibited by mutant p53 or to inhibit tumour-promoting 
pathways that are activated by mutant p53.  
 
RETRA 
Compounds that impair the interaction of mutantp53 with other target proteins could be 
a more general strategy to prevent the oncogenic effect of mutant p53s that share 
binding partners. 
The small-molecule RETRA (Reactivate transcriptional activity) as been reported to 
destabilize the p73-mutant p53 interaction (Kravchenko et al. 2008) thereby restoring 
the p73-mediated apoptosis. 
RETRA has been shown also to induce the transactivation of p53 target genes in mutant 
p53-bearing tumours and to prevent the growth of xenograft tumours in mice 
(Kravchenko et al. 2008). 
  
Statins 
Statins are a class of drugs largely used to lower the cellular cholesterol levels in 
patients with hypercholesterolemia by inhibiting the enzyme HMG-CoA-reductase 
(HMGCR) (Clendening & Penn 2012; Demierre et al. 2005). 
This enzyme catalyzes the production of mevalonic acid (MVA), which represents the 
rate-limiting step of cholesterol biosynthesis (the mevalonate pathway) and also 
regulates prenylation/ lipidation (farnesylation and geranyl-geranylation) of proteins.  
Prenylation is a post-translational modification of proteins by which a farnesyl- or 
geranylgeranyl moieties are added to a cysteine residue of target proteins involved in 
cellular adhesion, migration, and proliferation signaling (e.g., Rho, Rac, Cdc42, Ras) 
facilitating their attachment to cell membranes (Shimoyama 2011). 
In breast cancer cells, mutant p53 acts as a positive transcriptional cofactor for SREBPs, 
(Freed-Pastor et al., 2012), to regulate expression of several enzymes involved in the 
mevalonate pathway (Brown and Goldstein, 1997), leading to elevated expression of 
cholesterol biosynthesis enzymes and enhanced prenylation of proteins associated with 
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cancer progression; hence, inhibition of protein prenylation by statins leads to reduced 
malignancy of human breast cancer cells (Freed-Pastor et al. 2012). Interestingly, it was 
unveiled that activation and subcellular localization of YAP/TAZ, the main downstream 
effectors of the Hippo pathway, is mediated by prenylation and activation of Rho-
GTPases and inhibition of the rate-limiting enzyme of this pathway (HMG-CoA 
reductase) by statins opposes YAP/TAZ nuclear localization and transcriptional 
responses (Sorrentino et al. 2014).Thus, YAP/TAZ represent important executors of 
mutant p53 gain-of-function, acting downstream of the mutant p53-induced metabolic 
reprogramming is cancer cells. 
 
-Compounds that induce Synthetic Lethality  
Synthetic lethality is generally used for the condition where a mutation in a gene is not 
lethal by itself, but its combination with a drug or other gene mutations leads to cell 
death (Kaelin 2005). Induction of synthetic lethality for mutant p53 is an attractive 
approach as a therapeutic strategy since over 50% of human cancers have mutations in 
the p53 gene. In this regard, compounds that induce synthetic lethality should 
selectively kill cancer cells expressing mutant p53 without affecting normal cells 
carrying wild-type p53.  
 
BI-2536 PLK1 (polo-like kinase 1) inhibitors 
Another compound that is synthetic lethal to mutant p53 is BI-2536, an inhibiter of 
polo-like kinase 1 (PLK1), an enzyme that controls G2/M checkpoint.  
Transcriptome analyses revealed a consistent up-regulation of polo-like kinase 1 
(PLK1), as well as other genes controlling the G2/M transition, in breast (King et al. 
2012) cancers with mutant p53 expression; the presence of both coincided with a worse 
prognosis than cancers with either PLK1 upregulation or mutant p53 expression alone 
(King et al., 2012). Inhibition of PLK1 by BI-2536 significantly enhances cytotoxic 
effect of ionizing radiation in mutant p53 (p53S241F) and (p53R248W) overexpressing 
cancer cell line but it does not do so in parental (wild-type p53) cells (Sur et al. 2009). 
 
UCN01 
UCN0 is a protein kinase C inhibitor and a potent blocker of G2/M checkpoint of the 
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cell cycle. Interestingly, UCN-01 treatment enhances the cytotoxicity of gamma 
irradiation and induced G2/M cell cycle arrest in human lymphoma cells CA46 
(p53R248Q) and human colon carcinoma HT29 (p53R273H). Moreover human breast 
carcinoma MCF-7 cells defective for p53 function were more sensitive to cisplatin, 
upon treatment with UCN-01, with little effect on MCF7 cells having normal p53 
function (Wang et al. 1996).  
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AIM OF THE THESIS 
 
Mutation of the TP53 gene is the most frequent genetic lesion in human cancers and 
contributes to malignant transformation. Ninety percent of p53 alterations are missense 
mutations in the DNA-binding domain, which do not only abrogate its tumour 
suppressive functions, but also lead to the acquisition of new oncogenic functions 
(overall called gain of function - GOF), such as the ability to foster tumour progression, 
metastatic potential and drug resistance. Common features of mutant p53 proteins are 
their constitutive hyper-stabilization in cancer cells and their ability to establish aberrant 
protein complexes with several partners such as p63/p73, NF-Y, SREBPs, SP1 and Ets, 
affecting their biological activities. However, the pathways leading to mutant p53 
stabilization  in cancer cells have been only partially investigated and are still not 
completely understood.  
Inhibition of the pathways that cancer cells exploit for their survival and metastatic 
dissemination is a rational approach to selectively hit transformed cells with minimal 
effects on normal tissues. Thus, targeting mutant p53, which specifically accumulates in 
the majority of tumour cells, represents an attractive strategy for cancer therapy, in 
particular via the identification of molecules that reduce its protein amount. This notion 
is supported by the evidence that knocking-down mutant p53 from cancer cells that are 
addicted to its expression either by small molecules or by RNA interference is able to 
reduce their malignant progression. In this context, the discovery that HDACs and 
HSP90 proteins protect mutant p53 from proteasome-mediate degradation not only 
unveiled two important mechanisms of mutant p53 stabilization in cancer, but also led 
to the identification of 17-AAG and SAHA (respectively Hsp90 and HDAC inhibitors) 
as anticancer small molecules acting, at least in part, by blocking mutant p53 GOF. 
Unfortunately these drugs, due to the pleiotropic activities of their targets, cause large 
toxic effects in cancer patients and have failed several clinical trials. The identification 
of efficient and well-tolerated drugs that specifically target mutant p53 remains 
challenging; however, elucidation of mechanisms of mutant p53 stabilization in cancer 
cells would open new chances for the design of anticancer therapeutic strategies.  
The work presented in this thesis aimed to identify small molecules, from a library of 
FDA-approved compounds, able to reactivate the Mdm2-dependent degradation of 
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mutant p53 in cancer cells Since the mechanisms of action of all the used FDA-
approved compounds are well known, we reasoned that the identification of such 
molecules could also reveal new mechanisms of regulation of mutant p53 protein 
stability in cancer cells. The identified lead-compound could also clinically tested 
clinically tested it in breast cancer with high levels of mutant p53.  
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RESULTS  
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Identification of FDA-approved drugs that reduce mutant p53 levels 
To identify drugs able to reactivate the mutant p53 negative regulator Mdm2 in cancer 
cells, we performed a high-content, fluorescence-microscopy-based, high-throughput 
screening using a library of FDA (Food and Drug Administration)-approved drugs 
composed of a collection of 640 clinically-used compounds with known and well-
characterized bioactivity, safety and bioavailability (Sorrentino et al. 2014). Nuclear 
accumulation of mutant p53 proteins is a hallmark of a variety of human cancers, 
moreover tumour-specific mutant p53 hyperstabilization is crucial for manifestation of 
its GOF (Soussi & Béroud 2001; Rotter et al. 1983; Shaulsky et al. 1990). We thus 
monitored the effect on nuclear mutant p53 protein levels of each compound of the 
library added at two different concentrations (1 and 10 µM) to the culture medium of 
the breast cancer cell line MDA-MB-231 (Supplementary Figure A). SAHA, which 
belongs to the class of histone deacetylase inhibitors and has been found to strongly 
reduce the stability of mutant p53, was used as positive control (D Li et al. 2011). After 
24h, mutant p53 positive cells were detected by immunofluorescence and quantified 
through automated image analysis. As expected, MDA-MB-231 cells exhibited a strong 
mutant p53 nuclear staining, unaffected by most compounds. However, we were able to 
identify several drugs that significantly reduced the number of mutant p53 positive 
cells. In particular, filtering the results based on reproducibility, on dose-dependence 
and on manual image analysis, we identified as the best hits (Figure 8A-C): 
o Ouabain, a cardiac glycoside used for the treatment of congestive heart failure 
and atrial fibrillation. Ouabain is an inhibitor of Na+/K+-ATPases and increases 
the intracellular calcium concentration (Newman et al. 2008). In addition, the 
drug was also found to be beneficial to breast cancer patients (Stenkvist et al. 
1979) and was associated with a lower risk for leukemia, lymphoma, as well as 
kidney and urinary tract cancer (Haux et al. 2001);  
o Spiperone, a butyrophenone antipsychotic agent with dopamine and serotonin 
(5-HT) receptor antagonist properties (Gundlach et al. 1984)(Leysen et al. 
1978). Spiperone is a calcium regulator that specifically blocks canonical Wnt 
signaling by elevating intracellular calcium levels (Lu & Carson 2009);  
o Ivermectin, a derivative of avermectin B1 used for the treatment of the parasitic 
infections. It was unveiled that ivermectin leads cell death in leukemia cells 
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through chloride-dependent membrane hyperpolarization and generation of 
reactive oxygen species (ROS) (Sharmeen et al. 2010);  
o Thioridazine, an antipsychotic drug and D2 dopamine receptor antagonist.  
Moreover, we found that two classes of drugs, namely adrenergic agonists (e.g. 
Salmeterol) and mevalonate pathway inhibitors (statins), were strongly associated 
with reduction of mutant p53 levels (Figure 8 A-C). Indeed, many of the adrenergic 
agonists and all the statins present in the library scored positive as drugs able to 
reduce the number of mutant p53 positive cells. Of note, adrenergic agonists (e.g. 
Isoprenaline) and Ouabain have been already identified as p53 destabilizing agents, 
thus confirming the reliability of our screening (Wang et al. 2009).  
 
Statins reduce mutant p53 proteins stability in an Mdm2-dependent 
manner 
To gain insight into the mechanism of mutant p53 inhibition by the identified drugs, we 
monitored p53 mRNA levels in MDA-MB-231 cells upon drugs treatment. 
Interestingly, none of these compounds was able to reduce p53 mRNA levels, 
suggesting that the identified drugs reduce mutant p53 protein amount acting at the 
post-transcriptional level (Figure 9A).  
The aberrant stability of mutant p53 observed in cancer is not due to its inability to 
transactivate the Mdm2 gene. In fact, experiments performed in knock-in (KI) mice 
expressing mutant p53 R172H, demonstrated that mutant p53 protein is inherently 
unstable in normal tissues while only tumour cells display constitutive stabilization of 
mutant p53 (Haupt et al. 1997; Terzian et al. 2008; Lukashchuk & Vousden 2007). 
Therefore, during oncogenic transformation, one or more still not completely 
understood events occur that stabilize mutant p53. In this context, study by different 
groups demonstrated that the aberrant activation of Hsp90 chaperone machinery induces 
Mdm2 functional inactivation thus sustaining mutant p53 hyper stability (Figure 10G). 
Based on these premises, we hypothesized that the identified drugs could reduce mutant 
p53 levels by reactivating the inhibitory function of Mdm2 on mutant p53. To test this 
hypothesis, we used Nutlin, a cis-imidazoline drug which specifically inhibits the 
Mdm2-p53 interaction. Of note, Nutlin treatment rescued mutant p53 levels only in 
cells treated with the adrenoceptor agonist Salmeterol and the mevalonate pathway 
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inhibitor Cerivastatin, thus suggesting that β2-adrenergic receptor pathway and the 
mevalonate pathway control mutant p53 protein levels in a Mdm2-dependent manner 
(Figure 9B). Interestingly, activation of β2-adrenergic pathway has been already shown 
to trigger AKT-mediated activation of Mdm2 and also to promote Mdm2-dependent 
degradation of wild type p53 (Pääjärvi et al. 2005). Therefore, we focused our attention 
on the mevalonate pathway. 
Statins are a class of drugs clinically used to lower the plasma cholesterol levels in 
patients with cardiovascular diseases by inhibiting the enzyme HMG-CoA reductase 
(HMGCR). This enzyme catalyses the biosynthesis of mevalonic acid (MVA), which 
represents the rate-limiting step of cholesterol biosynthesis.  
Interestingly, mutant p53 has been identified as a crucial upstream activator of the 
mevalonate pathway in cancer cells by binding to and inducing the transcriptional 
activity of SREBPs (Sterol Regulatory Element Binding Proteins) transcription factors 
(Freed-Pastor et al. 2012). Activation of the mevalonate pathway, in turn, leads to 
increased protein prenylation, aberrant cell growth in 3D culture and disruption of 
mammary tissue architecture. However, our results suggest that mutant p53 could be not 
only an upstream regulator but also a downstream target of the mevalonate pathway. To 
assess whether the mevalonate pathway is a general regulator of mutant p53 proteins in 
different cellular contexts, we treated a panel of human tumour cell lines, derived from 
different tumour types, with Cerivastatin and monitored mutant p53 protein levels. As 
shown in Figure 10A, inhibition of the mevalonate pathway caused a strong reduction 
of mutant p53 protein levels in all the cell lines tested. Similar results were obtained 
treating cells with Simvastatin (Supplementary Figure B). The reduction of mutant p53 
levels was time-dependent and was maximal after 48 hours of treatment (Figure 10B). 
Moreover, statin treatment reduced also the level of exogenously overexpressed mutant 
p53 R280K in MDA-MB-231 cells, thus confirming that the mevalonate pathway 
sustains mutant p53 stability through post-transcriptional mechanisms (Figure 10C).  
All the mutant p53 proteins have been found to show different degrees of altered 
conformation. To understand whether statins act specifically on mutant p53 proteins 
with strong structural alteration, we stably expressed siRNA-resistant mutant p53 
R175H (which has a strong altered conformation) or R280K (which has an almost intact 
conformation) proteins in isogenic normal breast epithelial cells MCF10A depleted of 
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endogenous wild type p53. Of note, both mutant p53 proteins were affected by statin 
treatment, suggesting that the mevalonate pathway sustains the stability of mutant p53 
proteins, irrespectively of their structural features (Figure 10D). 
To further explore the mechanisms of mevalonate-dependent mutant p53 stabilization 
we performed cycloheximide (chx) experiments in MDA-MB-231 cells. Strikingly, 
Cerivastatin treatment strongly shortened mutant p53 half-life in a proteasome-
dependent manner (Figure 10E). Again, Mdm2 inhibition by means of Nutlin-3 
treatment rescued mutant p53 degradation (Figure 10E), thus suggesting that Mdm2 is 
responsible for mutant p53 degradation upon mevalonate pathway inhibition.  
Ubiquitination is a major mechanism by which mutant p53 is controlled by Mdm2 
(Esser et al. 2005; Nagata et al. 1999). In line with this, we found that statin treatment 
strongly increased ubiquitination of mutant p53 in MDA-MB-231 cells (Figure 10F).  
In cancer cells, mutant p53 proteins are engaged in stable complexes with Hsp90 
chaperone machinery, which is often upregulated in cancer (Wang & Chen 2003; Dun 
Li et al. 2011) (Kamal et al. 2003). This interaction results in a marked reduction of 
mutant p53 ubiquitination and degradation by the E3 ligases Mdm2 and CHIP (Esser et 
al. 2005; Nagata et al. 1999) (Figure 10G). Based on this premises, we hypothesized 
that statins might act by destroying the mutant p53-Hsp90 interaction thus reactivating 
the inhibitory activity of Mdm2 on mutant p53. Strikingly, we found that in MDA-MB-
231 cells, Cerivastatin treatment led to strong dissociation of mutant p53 from Hsp90, 
suggesting that the mevalonate pathway supports mutant p53 stabilization by promoting 
its interaction with the Hsp90 chaperone machinery (Figure 10H). 
Taken together, these data suggest that the mevalonate pathway inhibitors treatment of 
cancer cells restore the inherent mutant p53 instability by functionally reactivating the 
Mdm2 inhibitory effect on mutant p53. 
 
The Mevalonate Pathway is required for mutant p53 proteins stability 
To investigate whether the effects of statin were specifically mediated by the inhibition 
of HMGCR enzymatic activity and consequent reduction of intracellular mevalonate 
levels (Figure 11A), we added MVA to the culture medium of MDA-MB-231 cells 
treated with statin, thus bypassing the requirement of HMGCR enzymatic activity. 
Importantly, mutant p53 protein levels were completely rescued by MVA addition into 
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the medium, thus confirming that mutant p53 stability depends on intracellular 
mevalonate levels (Figure 11B).  
The identification of the mevalonate pathway as a key controller of mutant p53 stability, 
led us to investigate the upstream regulators of this metabolic signalling. All the 
enzymes of the mevalonate pathway, among which HMGCR, are under direct 
transcriptional control of SREBPs (sterol regulatory element-binding proteins) 
transcription factors (Figure 11A) (Brown & Goldstein 1997). SREBP1 and SREBP2 
localize into the endoplasmic reticulum as inactive membrane-bound precursors. 
However, when cells require sterols—for example, after reduction of lipoprotein 
concentration in plasma—SREBPs translocate to the Golgi where they undergo 
maturation by proteolytic cleavage, and enter the nucleus to transcribe the enzymes of 
the mevalonate pathway thus restoring cellular lipids homeostasis (Edwards et al. 2000; 
Horton et al. 2002). Based on our results, it is conceivable that SREBPs may regulate 
mutant p53 levels by modulating the mevalonate pathway. To investigate this, we 
inhibited SREBP1 and SREBP2 expression by siRNA transfection in MDA-MB-231 
cells maintained in medium with lipoprotein-depleted serum and we observed, along 
with reduction of the SREBP1/2 target gene SCD, a significative reduction of mutant 
p53 levels (Figure 11C). 
The Mevalonate kinase (MVK) gene encodes for a crucial kinase within the mevalonate 
pathway that phosphorylates MVA into mevalonate-5-phosphate. Mevalonate kinase 
deficiency is a pathologic condition caused by several mutations on the MVK gene, 
which causes accumulation of MVA and impairment of the metabolites produced from 
MVA. In particular, the mutation N301T in the MVK gene has been identified as a 
dominant-negative mutation able to inhibit the wild type MVK enzyme thus impairing 
the mevalonate pathway flow (Gibson et al. 1989). In order to inhibit the mevalonate 
pathway using a naturally occurring mutation on MVK, we transfected the MVK 
N301T construct in MDA-MB-231 cells. Of note, immunofluorescence analysis 
demonstrated that cells expressing the mutated form of MVK were also negative for 
mutant p53 expression (Figure 11D), confirming that inhibition of mevalonate pathway 
reduces mutant p53 levels. 
Downstream of mevalonate-5-phosphate, the enzyme farnesyl diphosphate synthase 
(FDPS) is required for the biosynthesis of geranyl pyrophosphate, a key precursor of 
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several mevalonate pathway products. Bisphosphonates (BPs) are FDA-approved 
compounds able to inhibit the mevalonate pathway by blocking the enzymatic activity 
of FDPS (Shipman et al. 1998) (Räikkönen et al. 2010) (Cl??zardin 2011). BPs are 
clinically used to treat osteoporosis, however several preclinical and clinical data 
suggest that BPs exert anticancer effects in different tumours, among which breast 
cancer. To test whether inhibition of mevalonate pathway by means of BPs affects 
mutant p53 levels in cancer cells, we treated MDA-MB-231 cells with Zoledronic Acid 
(ZA), a clinically-used BPs. As expected, similarly to statin treatment, ZA induced a 
strong reduction of mutant p53 protein levels (Figure 11E).  
To investigate whether the mevalonate pathway controls mutant p53 protein levels in 
vivo, we orthotopically injected MDA-MB-231 cells in the flank of 
immunocompromised mice and, after tumour establishment, we treated mice with 
zoledronic acid. As shown in Figure 11F, tumours from mice receiving ZA showed a 
robust reduction of mutant p53 levels.  
These results demonstrate that mutant p53 hyper stability is under metabolic control by 
the mevalonate pathway and that the genetic or pharmacological inhibition of this 
metabolic signal, at different levels, prevents mutant p53 accumulation in cancer cells.  
 
Geranylgeranyl pyrophosphate mediates mevalonate-dependent 
mutant p53 stabilization 
The mevalonate pathway is essential for the de novo biosynthesis of cholesterol but is 
also in charge for the production of other key metabolites among which isoprenoids 
(e.g. farnesyl pyrophosphate and geranylgeranyl pyrophosphate) (Figure 12A) (Repko 
& Maltese 1989). To gain insights into the molecular mechanisms controlling mutant 
p53 stabilization downstream of MVA, we inhibited specific enzymes of the 
mevalonate pathway to identify the metabolic intermediate responsible for mutant p53 
regulation (Figure 12A). In particular, we inhibited cholesterol biosynthesis by means 
of ym-53601 (inhibitor of squalene synthase); protein farnesylation by means of fti-277 
(inhibitor of the farnesyl transferase); and protein geranylgeranylation by means of ggti-
298 (inhibitor of geranylgeranyl transferase I). Interestingly, only the geranylgeranyl 
transferase I (GGT-I) inhibitor GGTI-298 was able to reproduce the effect of statins on 
mutant p53, whereas the inhibition of squalene synthase or of farnesyl transferase had 
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no effect (Figure 12B). Moreover, GGTI-298 treatment reduced the interaction between 
Hsp90 and mutant p53 (Figure 12C). 
These results suggest that the mevalonate pathway intermediate responsible for mutant 
p53 stability is geranygeranyl pyrophosphate. Consistent with this, GGPP addiction to 
culture medium almost completely rescued the mutant p53 levels in statin-treated cells 
(Figure 12D). These data indicate that protein geranylgeranylation is required for 
aberrant mutant p53 stability.  
Geranylgeranylation is a crucial post-translational modification (PTM) of proteins that 
requires the attachment of GGPP, a 20-carbon lipophilic isoprene unitss derived from 
the mevalonate pathway, to one cysteine residue at the carboxy-terminal of several 
proteins (Shimoyama 2011). The main biological function of geranylgeranylation is to 
anchor proteins to cellular membranes. Rho-GTPases represent one of the main families 
of proteins which are geranylgeranylated and this PTM is required for their activation. 
Indeed, statin-induced GGPP reduction has been found to inhibit the enzymatic activity 
of RhoA (Figure 12E) (Sorrentino et al. 2014). Interestingly, RhoA has been recently 
identified as a key mediator of the anti-tumour activity of statins (Sorrentino et al. 2014) 
Therefore, we tested whether statins were able to reduce mutant p53 levels by affecting 
the activity of RhoA. To this aim we decided to experimentally bypass the requirement 
of geranylgeranylation for RhoA membrane attachment, and verify whether mutant p53 
protein levels were rescued upon geranylgeranyl transferase inhibition. For this, we 
used a mutant GFP–RhoA bearing a C-terminal consensus for farnesylation (RhoA-F) 
instead of its natural geranylgeranylation motif (Supplementary Figure C). Indeed, 
farnesylation is an alternative PTM for membrane localization of several small GTPases 
(for example, Ras). As shown in Figure 12G, although RhoA-F protein was completely 
insensitive to geranylgeranyl transferase I inhibition (Figure 12F), mutant p53 levels 
were still reduced by GTI-298 treatment. These results demonstrate that RhoA is not 
involved in the regulation of mutant p53 stability downstream of mevalonate pathway 
and suggest that another geranylgeranylated protein controls mutant p53 levels in cancer 
cells.  
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Statins exert antitumour effects preferentially in mutant p53-
harbouring tumour cells 
Genetic and pharmacological ablation of mutant p53 proteins in tumours have been 
shown to have positive therapeutic effects in vivo, since those tumours show addiction 
to mutant p53 gain-of-function (Bossi et al. 2006) (Bossi et al. 2008) (Alexandrova et 
al. 2015) (Freed-Pastor et al. 2012). So far, the pharmacological inhibition of Hsp90 
chaperone is the only reliable clinical strategy to achieve this goal. Indeed, Hsp90 
inhibition in mice significantly extended the survival of mutant p53 knock-in mice by 
inducing mutant p53 degradation, growth arrest and apoptosis in tumour cells (D Li et 
al. 2011) (Alexandrova et al. 2015). Our results suggest that mevalonate pathway 
inhibitors could significantly curb the GOF activities of mutant p53 proteins, and thus 
might exert anticancer activity preferentially in p53-harbouring tumours. To test this 
hypothesis, we employed different assays on multiple human cancer cell lines with 
different p53 status. Interestingly, colony formation assay demonstrated that 
Cerivastatin reduces cell proliferation by reducing intracellular GGPP levels (Figure 
13A and 13B). Moreover, colony formation and BrdU assay showed that Cerivastatin is 
significantly more active in cancer cell lines harbouring mutant p53 (Figure 13A-C). 
Interestingly, Cerivastatin induced massive apoptosis in mutant p53-harbouring cells as 
demonstrated by Caspase 3 cleavage (13D), while wild type p53 and p53-null cancer 
cells were almost unaffected by Cerivastatin treatment (Figure 13A-D).  
To understand whether statins induce cell growth arrest and apoptosis by reactivating 
the wild type functions of mutant p53 proteins, we monitored the expression of p21, the 
most relevant p53 target gene, after statin treatment. As shown in Figure 14E, 
Cerivastatin was able to induce only a slight increase of p21 expression, which was not 
due to wild type p53 reactivation, as demonstrated by the fact that p21 levels increase 
also after knocking-down p53 in statin-treated cells. 
Taken together, these results indicate that statins exert strong anti-tumour activity in 
mutant p53-expressing human cancer cell lines, with reduced effects in tumours 
harbouring wild type p53.  
  
	 58	
Statins counteract mutant p53 gain-of-function in cancer cells 
One of the most critical aspects of mutant p53-dependent metastatic phenotype is the 
induction of migration and invasion. Mechanistically, mutant p53 has been found to 
enhance migration by sequestering and blocking the p63-mediated transcriptional 
induction of the anti-metastatic genes Sharp1 and CCNG2 (Adorno, Cordenonsi, 
Montagner, Dupont, Wong, Hann, Solari, Bobisse, Rondina, Guzzardo, Anna R Parenti, 
et al. 2009) (Figure 14A). In line with this, we found that Cerivastatin treatment in 
highly metastatic MDA-MB-231 cells, strongly rescued the expression of Sharp1 and 
CCNG2, likely caused by reduction of mutant p53 levels and consequent reactivation of 
p63 (Figure 14B). A crucial determinant of mutant p53-p63 interaction is the Prolyl-
isomerase Pin1. Indeed, Pin1 promotes mutant p53-dependent aggressiveness in breast 
cancer by reinforcing mutant p53-p63 interaction and thus fostering the repression of 
p63-target genes (Javier E Girardini et al. 2011) (Figure 15A). Moreover, Pin1 and 
mutant p53 induce a specific set of target genes to fully establish tumour aggressive 
behaviour (Figure 14A). In particular, ten mutant p53/Pin1 target genes have been 
identified as key effectors of mutant p53 GOF and strongly correlate with poor clinical 
outcome. Among them, the DEPDC1 gene was identified as a the main mediator of 
mutant p53-induced cell migration (Javier E Girardini et al. 2011). Interestingly, we 
found that Cerivastatin treatment reduced the expression of mutant p53/Pin1 target 
genes, in particular of DEPDC1 (Figure 14C and 14D). In line with this, Cerivastatin 
treatment strongly suppressed the migratory capability of MDA-MB-231 cells (Figure 
14E), confirming that mevalonate pathway inhibitors efficiently blunt mutant p53 GOF 
in cancer cells.   
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DISCUSSION AND FUTURE PERSPECTIVES  
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Missense p53 mutants accumulate in almost 50% of human tumours and their aberrant 
expression, due to extended half life, is necessary to confer oncogenic features to cancer 
cells (gain-of-function) (Cyriac Kandoth, Michael D. McLellan, Fabio Vandin, Kai Ye 
2013). Therefore molecules able to target the mechanism governing the protein stability 
of mutant p53 could have great clinical value. Although the molecular events 
responsible for mutant p53 stabilization in cancer cells are still poorly understood, 
several studies pointed out a crucial role for the Hsp90 chaperone machinery in 
controlling the mutant p53 protein stability. The multi-complex Hsp90 chaperone 
machinery is often altered in several human cancers and this evidence, at least in part, 
accounts for mutant p53 hyper stabilization specifically in tumour tissues.  
Genetic and pharmacological reduction of mutant p53 protein levels in human tumour 
cells showed strong therapeutic potential, in preclinical settings (Bossi et al. 2008; Bossi 
et al. 2006; D Li et al. 2011), in terms of reduction of cell proliferation and migration 
and increased chemosensitivity. Based on this notion, the systematic identification of 
well tolerated small molecules capable of reducing mutant p53 levels in human tumour 
cells could provide a great opportunity to blunt mutant p53 gain of function activities in 
cancer. Furthermore, the dissection of the mechanism of mutant p53 stabilization in 
cancer cells could expand our understanding of this process unveiling new pathways 
potentially targetable. Along this line, the discovery that mutant p53 is stabilized by a 
chaperone machinery composed of several proteins, among which HDAC6 and HSP90, 
led to the identification of 17-AAG and SAHA (respectively Hsp90 and HDAC 
inhibitors) as anticancer small molecules acting, at least in part, by blocking mutant p53 
(Alexandrova et al. 2015; D Li et al. 2011).  
In this thesis we describe the identification of novel regulators of mutant p53 
stabilization in cancer cells, identified trough a screening of a library of FDA-approved 
compounds for their ability to reduce mutant p53 levels. This approach allowed us to 
identify several known and unknown mutant p53-destabilizing drugs. We focused on 
statins and show, for the first time, that the metabolic mevalonate pathway has a strong 
impact on stabilization of several p53 mutants both in vitro (in a variety of human 
cancer cells lines) and in vivo (in xenograft experiments).  
The mevalonate pathway is essentially required for the biosynthesis of crucial 
metabolites such as cholesterol, dolichol, ubiquinone and isoprenoids. Despite this 
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pathway has been extensively studied in the context of cardiovascular diseases, recent 
reports have pointed out a crucial role of a dysregulated mevalonate pathway in human 
cancers. Interestingly, mutant p53 has been found to associate with mevalonate pathway 
gene promoters, via SREBP transcription factors, and to aberrantly activate the 
biosynthesis of isoprenoids (Freed-Pastor et al. 2012). 
Our results clearly demonstrate that mutant p53 and the mevalonate pathway are 
engaged in a positive circuit with mutant p53. Indeed mutant p53 acts as transcriptional 
cofactor of SREBP proteins, thus increasing the levels of mevalonate pathway 
intermediates which in turn sustain mutant p53 protein stability. Therefore, mutant p53 
acts not only as an upstream activator but also as a downstream mediator of aberrant 
activation of this metabolic pathway in cancer cells. 
Recently, we and others demonstrated that the transcription cofactor YAP, the main 
effector of the Hippo pathway, is positively controlled by the mevalonate pathway 
through prenylation of Rho-GTPases (Sorrentino et al. 2014). We also characterised the 
physical and functional association of YAP with mutant p53 proteins which is 
functional for activation of NF-Y transcriptional activity on the promoters of cell cycle-
related genes (Silvia Di Agostino et al. 2015; Di Agostino et al. 2006). Thus, the 
mevalonate pathway could sustain the oncogenic actions of mutant p53 in several ways, 
by increasing its stability and by favouring its recruitment into pro-oncogenic 
transcriptional complexes. 
Mechanistically, our results suggest that activation of the mevalonate pathway protects 
mutant p53 from Mdm2-mediated degradation by the proteasome. In particular, we 
found that inhibition of the mevalonate pathway (by using statins, bisphosphonates and 
geranylgeranyl transferase inhibitors) reduces the engament of mutant p53 in the Hsp90 
chaperone machinery thus restoring the ability of Mdm2 to poly-ubiquitinate mutant 
p53.  
Although in our experiments we did not investigated the effects of mevalonate levels on 
Mdm2 enzymatic activation, work done in cells from liver cancer harbouring wild type 
p53, showed that statins trigger AKT-mediated Mdm2 phosphorylation, which is known 
to be required for its enzymatic activity. Thus, it is possible that the mevalonate 
pathway acts at different levels to control mutant p53 stability by both controlling 
mutant p53-Hsp90 interaction and the enzymatic activity of Mdm2.  
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Beyond Mdm2, the E3 ubiquitin ligase CHIP has been identified as a negative regulator 
of mutant p53 proteins. Similarly to Mdm2, binding of mutant p53 to Hsp90 protects 
mutant p53 from CHIP-mediated ubiquitination and degradation. Our results that statins 
inhibit the Hsp90-mutant p53 interaction suggest that reduction of mevalonate levels 
could also restore the negative activity of CHIP over mutant p53 and further 
investigation to test this hypothesis will be performed. 
Experiments aimed at identifying the specific intermediate of the mevalonate pathway 
responsible for the mutant p53-Hsp90 interaction and consequent mutant p53 hyper 
stabilization, showed that in cancer cells mutant p53 turnover depends on the 
intracellular amount of geranylgeranyl pyrophosphate (GGPP), which is required for 
protein prenylation. The mechanisms by which GGPP controls the interaction of mutant 
p53 with Hsp90 are still unknown, and might involve the alteration of post-translational 
modification patterns on mutant p53 or Hsp90, such as phosphorylation and acetylation, 
or alteration of protein structure and folding. However, our results with geranylgeranyl 
transferase inhibitors implicate that protein geranylgeranylation is involved in the 
control of mutant p53 stability.  In this context, we recently found that RhoGTPases, in 
particular RhoA, mediate the effects of GGPP on YAP/TAZ. However, our data exclude 
a role for RhoA in controlling mutant p53 stability and implicate that at least another 
geranylgeranylated protein controls mutant p53 protein levels. Our ongoing experiments 
are focused on the identification of this protein.   
Cancer cells are addicted to mutant p53 and induction of mutant p53 degradation 
represents an effective approach to blunt its GOF. Indeed, reduction of mutant p53 
protein levels results in the release and activation of the oncosuppressors proteins such 
as p73 and p63, triggering their antitumoural transcription program. In line with this we 
demonstrate that statins exert anti-proliferative activity preferentially in those cells in 
which p63 oncosuppressive activities are restrained by the aberrant expression of 
mutant p53 proteins.  
Several studies attempted to demonstrate a significative correlation between statin use 
and reduced cancer-related(Chan et al. 2003). 
However, the evidences are still debatable and context-dependent. Our results suggest 
that in order to evaluate the possible antitumour activity of statins in human patients, the 
mutational status of p53 should be taken into account. Moreover, our results suggest the 
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possibility to assess the antitumour activities of statins, in combination with standard 
chemotherapy, specifically in patients with mutant p53-bearing tumours.  
One elegant and powerful approach to inhibit mutant p53 in cancer cells is provided by 
several compounds able to bind mutant p53 proteins and reactivate its wild type 
function (Bykov, Issaeva, Shilov, et al. 2002; Parrales & Iwakuma 2015; Guida et al. 
2008; Bykov, Issaeva, Selivanova, et al. 2002; V. J. Bykov et al. 2005). Conversely, 
statins were unable to reactivate the oncosuppressive transcriptional program of p53 as 
demonstrated by the fact that the induction of the p53-target gene p21 by statins was 
largely p53-independent. Nevertheless, statins triggered activation of anti-metastatic 
p63 target genes and inhibition of the pro-oncogenic mutant-p53/Pin1 target genes 
expression.  
All in all, the discovery that mutant p53 stability is controlled by the mevalonate 
pathway via protein geranylgeranylation reveals an unexpected metabolic layer of 
regulation of mutant p53 and provides the rational for the clinical use of mevalonate 
pathway inhibitors in cancers harbouring missense mutant p53.   
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EXPERIMENTAL PROCEDURES  
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Cell lines, culture conditions, and treatments  
MDA-MB-231 (p53R280K), MDA-MB-468 (p53R273H), SUM149 (mutp53M237I) 
and BT-549 (mutp53R249S) are triple-negative breast cancer cells (TNBC). SK-BR-3 
(p53R175H) are HER2-overexpressing breast cancer cells. T47D (mutp53L194F) 
human ductal breast carcinoma breast cancer cell line. Mahlavu (mutp53R249S) are 
hepatocellular carcinoma cell line. U2OS, osteosarcoma cell line, and MCF-7, human 
adenocarcinoma cell line, express wild-type p53, while H1299, a non-small cell lung 
cancer cell line, are p53 null. MCF10A ,mammary ephitelial cells expressing wild-type 
p53. 
MDA-MB-231, MDA-MB-468, BT-549, SKBR-3, U20S and T47D cells were cultured 
in DMEM (LONZA) supplemented with 10% FBS (Fetal Bovine Serum) and with 1% 
antibiotics (penicillin 100U/mL and streptomycin 10µg/mL). SUM 149 cells were 
cultured in DMEM/F12 (LONZA) (1:1) supplemented with 5% HS (Horse Serum) and 
with 1% antibiotics. Mahlavu cells were cultured in EMEM (Sigma) supplemented with 
10% FBS (Fetal Bovine Serum), with 1% antibiotics (penicillin 100U/mL and 
streptomycin 10µg/mL), 1% MEM NEAA (Minimum essential medium non-essential 
amino acids) and 1% Glutamax. H1299 cells were cultured in RPMI medium RPMI 
1640 with 10% FBS and 1% antibiotics. MCF7 cells were cultured in EMEM (Sigma) 
supplemented with 10% FBS (Fetal Bovine Serum), with 1% antibiotics (penicillin 
100U/mL and streptomycin 10µg/mL) and 1% MEM NEAA (Minimum essential 
medium non-essential amino acids. MCF10A (sh stable and mutant p53 expressing cell 
lines) cells were mainetened in DMEM:F12 Ham’s medium 1:1, supplemented with 5% 
horse serum, insulin (10 µg/ml), hydrocortinose (0,5 µg/ml) and epidermal growth 
factor (EGF 20ng/ml) and with addition of selection antibiotics. 
Treatment with inhibitors: Nutil-3 (10µM), Zoledronic Acid (ZA) (50µM), FTI-277 
(1µM), YM-53601 (1µM), GTI-298 (1µM), Mevalonic acid ( MVA) (0.5 mM), GGPP 
(20µM) alone or with Cerivastatin, Cycloheximide (CHX) (50 µM),  MG132 (50mM). 
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Reagents and plasmids: 
The library of FDA-approved drugs (Screen-Well FDA-Approved Drug Library, 640 
chemical compounds dissolved at 10mM in DMSO) was obtained from Enzo Life 
Sciences (Enzo Life Sciences Inc.,Plymouth Meeting, PA, USA). 
The following compounds were purchased from Sigma Aldrich: Cerivastatin 
(SML0005), Simvastatin (S6196), FTI-277 (F9803), GGTI-298 (G5169), DL-
Mevalonic Acid 5-Phosphate (79849), Geranylgeranyl Pyrophosphate (#G6025), 
Zoledronic Acid (SML0223), YM-53601 (18113) was purchased from Cayman.  
pSR-shRNAp53 puroR used to stably silence TP53 expression was a kind of R.Agami. 
N-terminally HA-tagged p53 constructs: pMSCV-HA-P53R280H was generated by first 
introducing 4 silent point mutations in the region targeted by p53 siRNA I/shRNA (the 
same target sequence) by site directed mutagenesis in pcDNA-HA-p53, subsequent 
introduction of missense point mutation and subcloning of sequenced p53 cds 
constructs to pMSCV-HA-BlastR retroviral vectorto obtain pMSCV with N-terminally 
HA-tagged p53 cds. 
 
High Content Screening 
For the screening experiments, MDA-MB-231 cells (3.0×103 per well) were seeded on 
black clear-bottom 384-well plates (PerkinElmer). Twenty-four hours later, the FDA-
approved drugs were transferred robotically from library stock plates (0.1mM and 1mM 
in DMSO) to the plates containing the cells; controls were added to columns 1, 2, 23 
and 24 of each plate. Cells were fixed at 48 h after plating, i.e. 24h after addition of 
drugs, and processed immediately for immunofluorescence. Briefly, cells were fixed 
with 4% paraformaldehyde for 15 min, permeabilized with 0.5% Triton X-100 in 
phosphate buffered saline (PBS) solution for 10 min, followed by 30 min blocking in 
3% FBS. Cells were then incubated with a mouse antibody against mutant p53 (Santa 
Cruz Biotechnology) diluted in blocking solution for 1 h. Cells were further washed 
with PBS and incubated for 1h with a secondary antibody conjugated to Alexa Fluor-
594 (Life Technologies), and stained with Hoechst 33342 (Life Technologies).  
Image acquisition was performed using an ImageXpress Micro automated high-content 
screening fluorescence microscope (Molecular Devices) at a 10x magnification; a total 
of 16 images were acquired per wavelength, well and replicate, corresponding to ca. 
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4,500 cells analyzed per experimental condition and replicate. Image analysis to identify 
cells presenting mutant p53 signal was performed using the ‘Multi-Wavelength 
Translocation’ application module implemented in MetaXpress software (Molecular 
Devices).  
Screening was performed in duplicate, at two drug concentrations (1µM and 10µM); 
final concentration of DMSO in the culture medium was 1% (v/v) for all experimental 
conditions. The screening was performed at the ICGEB High-Throughput Screening 
Facility (http://www.icgeb.org/high-throughput-screening.html). 
 
Transfections 
siRNA transfections were performed with Lipofectamine RNAi-MAX (Life 
technologies) in antibiotics-free medium according to manufacturer instructions.  
siRNAs were previously described and sequences are:  
 
Target siRNA sense sequence 
Control  Allstars neg.control siRNA Quiagen #1027281 
SREBP-1 5’-AUCUCUGAAGGAUCUGGUG-3’ 
SREBP-2  5’GCCCUCUAUUGGAUGAUGC-3’ 
 
 
Negative control siRNA was: AllStars negative control siRNA Qiagen 1027281. 
In detail RNAi-MAX Lipofectamine was diluited in Optimem medium (Invitrogen) 
and, separately, siRNA-p53, siSREBP1,SREBP2 and siRNA-control (siRNA Qiagen 
1027281) were also diluited in Optimem medium; after 5 minutes of incubation, RNAi-
MAX Lipofectamine solution was added to siRNA solutions and they were incubated 
for 20 minutes; mixed solutions were finally added to the medium of cells, plated 24 
hours before. After 48 hours from transfections, cells were analysed.  
DNA transfections were performed in MDA-MB 231 cell with Lipofectamine 2000 
(Invitrogen) in antibiotic-free medium according to the manufactured instructions.  
Transfection was performed with Lipofectamine 2000 (Invitrogen) in antibiotic-free 
medium according to the manufactured instructions. In details, Lipofectamine was 
diluited in Optimem medium (Invitrogen) and separately another solution with pLPC-
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GFP or pLPC-GFP-RhoA and Optimem was prepared; after 5 minutes of incubation, 
Lipofectamine solution was added to pLPC-GFP or pLPC-GFP-RhoA or Myc-MVK-
N301T solution and they were incubated for 20 minutes; mixed solutions were finally 
added to the medium of cells, plated 24 hours before. After 24 hours from transfection, 
cells transfected with pLPC-GFP or pLPC-GFP-RhoA were treated with GTI-298 or 
cerivastatin for 24 hours, and then examined by fluorescence microscopy. 
 
Quantitative Real-Time PCR  
Cells were harvested in Qiazol lysis reagent (Qiagen) for total RNA extraction, and 
contaminant DNA was removed by DNase treatment. qRT-PCR analyses were carried 
out on retrotranscribed cDNAs with Quantitect reverse transcription kit (Qiagen) and 
analyzed with Biorad CFX Manager software. Experiments were performed at least 
three times, with duplicate replicates. Expression levels are always given relative to 
histone H3. Primers sequences have been previously described (Girardini J., et al., 
2011) 
 
Proteins extraction  
Plated cells were lysed with Lysis Buffer (NP40 1%, Tris-HCL pH=7.5% 50mM, NaCl 
300mM, EDTA 1mM) solution, supplemented with protease inhibitors (CLAP 0.1mM 
and PMSF 1mM) and with phosphatase inhibitors (NaF 5mM and Na3VO4 1mM), and 
were harvested. Cells were then centrifuged at 10,000 rpm for 10 minutes at 4°C. 
Concentration of proteins in the lysate was then quantified with the spectroscopic 
analytical procedure Bradford Protein Assay (Bio> Rad). Samples obtained were 
denatured in Laemmli Sample Buffer 2X or 6X and boiled for Electrophoresis.  
 
Western blot 
Western blotting allows the antibody detection of specific proteins from extracts made 
from cells. In order to make the proteins accessible to antibody detection they were 
moved from within the gel onto a membrane made of nitrocellulose with the blotter 
Trans-Blot Transfer Cell. The membrane was incubated in Blotto-Tween 20 solution 
(milk powder 5% w/v in PBS solution, added with Tween20 0.2% w/v) for 30 minutes 
and then incubated with primary antibody over-night. The next day, membrane was 
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incubated with secondary antibody for at least 30 minutes and finally developed in 
photographic plates with the solution kits ECL or ECL-Plus (Amersharm).  
The antibodies used for western blot were: mouse monoclonal p53 (DO1) (1:1000) 
(Santa Cruz Biothecnology); Anti-actin (1:2000) is C11 (Sigma); Anti-vinculin 
(1:5000) is V4505 (Sigma);  
 
Co-immuno precipitation. 
Co-IP experiments with endogenous proteins were performed using Co-IP buffer (NaCl 
120mM, Tris-HCl pH8 20mM, EDTA 1mM, NP40 0,5%) with protease inhibitors. 
Samples were cleared by centrifugation for 30 min at 13,000g at 4 °C and incubated for 
2 h at 4 °C with anti-p53 antibody (DO-1; Santa Cruz). After 1 h incubation with 
protein G-Sepharose (GE Healthcare), immunoprecipitates were washed three times in 
Co-IP buffer, resuspended in sample buffer, and analyzed by immunoblotting. To avoid 
cross-reaction with Ig heavy chains, immunoprecipitated p53 was detected using HRP-
conjugated DO-1 monoclonal antibody (Santa Cruz).  
For ubiquitination assays, cells were lysed in 2% SDS, 150 mM NaCl, 10 mM Tris-
HCl, pH 8.0, 1 mM PMSF, 5 mM NaF, 1mM Na3VO4, 0,5% (v/v) sodium 
deoxycholate with protease inhibitor cocktail (Sigma-Aldrich) and Ubiquitin Aldeyde 
50 ng/ml. Cell lysates were diluted in IP buffer: 10 mM Tris-HCl, pH8.0, 150 mM 
NaCl, 2 mM EDTA, 1% Triton. The anti-p53 antibody (DO-1; Santa Cruz) was 
covalently bound to protein G Sepharose (Amersham Biosciences, GE Healthcare, 
Munich, Germany) using 5 mg/ml dimethylpimelimidate (Pierce Biosciences, Thermo 
Fisher Scientific, Bonn, Germany).  
 
Colony formation assay 
Cells ( 5x103 ) were plated on 6cm plates. The day after the medium was supplemented 
with cerivastatin (0,1 µM) alone or in combination with geranygeranyl pyrophosphate 
(GGPP) 20µM. After 6 days, cells were fixed with 4% paraformaldehyde (PFA) and 
stained for 30 min with Giemsa (FLuka) diluted solution 1:5 in water. Plates washed 
with water and dried were scanned. 
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Migration and invasion assays. For migration analysis, transfected cells (1x105) were 
plated on 24 well PET inserts (8.0 µm pore size, Falcon), according to the 
manufacturer’s instructions. For invasion assays cells (1x105) were plated on matrigel-
coated filters (8.0 µm pore size, Falcon) and the lower part of the chamber was filled 
with DCCM medium. After 16 h cells on the upper part of the membrane were removed 
with a cotton swab and cells that passed through the filter were fixed in 4% PFA, 
stained with 0.05% crystal violet and counted.  
 
Viability assay 
Cells (104 per well) were plated in 96-well plates and treated with cerivastatin (0,1 µM)  
for 96h. Cell viability was assayed with ATPlite (Perkin Elmer) according to 
manufacturer instructions using EnSpire Multilabel Reader (Perkin Elmer). 
 
Brdu incorporation assay 
Cells (3x104) were plated in 24-well plates and treated with cerivastatin (0,1 µM). 
After 24 h from the treatment, the DNA precursor bromodeoxyuridine (BrdU) (1:1000) 
was added to the medium for 12-2h before fixation. 
Briefly, cells were fixed in 4% paraformaldehyde for 10 min, whashed in PBS, 
permeabilized with Triton 0.1% for 10 min and washed 3 times with NaOH 50mM 
solution and washed in PBS. Primary anti BrdU antibody solution (1:2 dilution), to 
detect bromodeoxyuridine (BrdU) incorporated, was used for 2h at 37°C and Goat anti-
mouse Alexa Fluor 568 (Life Technologies) as secondary antibody for 1h a 37°C. 
Nuclei were counterstained with Hoechst 33342 (Life Technologies). 
 
Mice and animal care  
For in vivo studies, one million of MDA-MB-231 cells were resuspended in 100 µl of 
DMEM, injected into the mammary fat of previously anesthetized 7 weeks old SCID 
female mice (1-3% isoflurane, Merial Italia S.p.A, Italy) as previously described. At day 
12 after cell injection, mice were subjected to intravenous injection of zoledronic acid 
([1-hydroxy-2- (1H-imidazoledronic acid-1-yl) ethylidene] (200µg/Kg body weight), 
every 4 days until the end of the experiment (day 40). The mice were used and housed 
in a specific pathogen-free (SPF) animal facility. Procedures involving animals and 
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their care were performed in conformity with institutional guidelines (D.L. 116/92 and 
subsequent complementing circulars) and all experimental protocols were approved by 
the ethical Committee of the University of Padua (CEASA). At day 40 the animals were 
sacrificed and the primary tumours were extracted and directly frozen in liquid nitrogen 
to perform molecular analyses.  
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Figure 8. Identification of FDA-approved drugs that reduce mutant p53 levels. 
(A) Results of high-content screening. Mutant p53 positive cells were detected by 
immunofluorescence and quantified through automated image analysis. Yellow circles 
are adrenergic agonists; orange circles are statins; red circles is SAHA. (B) 
Representative images of immunofluorescence from the screening.	MDA-MB-231 cells 
stained for Hoechst (blue) and mutant p53 (red) treated with dimethylsulphoxide 
(DMSO) or with 10µM of the indicated drugs for 48h. (C) p53 protein levels in MDA-
MB-231 cells treated with dimethylsulphoxide (DMSO)(-) or with the indicated drugs 
from the screening (+).  
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Figure 9. Statins reduce mutant p53 proteins stability in an Mdm2-dependent 
manner. 
(A) p53 mRNA levels were analyzed by qRT-PCR in cDNA obtained from MDA-MB 
231-cells untreated (black bars) or treated (red bars) with the identified drugs. Cells 
were treated as in Figure 1B. (B) Western blot of p53 protein levels from lysates of 
MDM-MB-231 cells treated with Nutlin-3 alone or in combination with the indicated 
drugs.  Cells were treated with  Nutlin-3 10µM for 12h before the treatment with the 
single hit drugs for 48h.  
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Figure 10. Inhibition of the Mevalonate pathway destabilizes mutant p53 proteins 
via proteasome-mediated degradation in different cellular contexts. 
(A) p53 protein levels were analyzed by Western blot in a panel of human tumour cell 
lines. Cells were treated with Cerivastatin 1 µM for 48 h. (B) Western blot analysis of 
p53 protein levels upon treatment of MDA-MB-231 cells with Cerivastatin 1 µM for the 
indicated times. (C) Western blot analysis of p53 protein levels in MDA-MB-231 cells 
expressing pcDNA3-HA-p53R280K vector untreated (-) or treated (+) with Cerivastatin 
1 µM for 48 h. (D) p53 protein levels were analyzed by Western blot in normal breast 
epithelial cells MCF10A depleted of endogenous p53 and stably expressing either 
siRNA-resistant mutant p53 R175H or R280K. Cells were treated for 48h with 
Cerivastatin 1 µM (+). (E) Cycloheximide (CHX) experiments in MDA-MB-231 cells. 
Cells were pre-treated with Cerivastatin (1 µM), alone or with nutlin (10 µM) and after 
24h cells were treated with CHX (50 µM) for the indicated times. The proteasome 
inhibitor MG132 (50mM) was added to the last time point. (F) MDA-MB-231 cells 
were transfected with constructs expressing HA-ubiquitin and pcDNA3-p53R280K, 
then treated with Cerivastatin 1 µM for 48h. Ubiquitylated mutant p53 was detected by 
IP followed by anti-HA western blot. (G) Schematic representation of the mechanism of 
mutant p53 stabilization in cancer cells. (H) Mutant p53 was immunoprecipitated from 
lysates of MDA-MB-231 cells untreated (-) or treated (+) with Cerivastatin 1 or 10 µM 
for 24h. Co-immuniprecipitated Hsp90 and Mdm2 were detected by Western blot.  
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Figure 11. The Mevalonate Pathway is required for mutant p53 proteins stability. 
(A) Schematic overview of the enzymes of the mevalonate pathway. Enzymes are 
shown in red and inhibitors in blue. (B) Western blot analysis of p53 in MDA-MB-231 
cells treated with Cervistatin 1µM (CER) alone or with mevalonic acid (MVA) 0,5 mM 
for 48h. C) Western blot analysis of p53 in MDA-MB-231 cells transfected with 
siRNAs specific for SREBP1 (BP1) or SREBP2 (BP2) and SREBP1/2 together (BP1/2) 
for 48h. D) Myc-MVK-N301T was transiently expressed in MDA-MB-231. p53 
expression was analysed by immunofluorescence. E) p53 protein levels are show by 
western blot analysis in cells untreated or treated with Zoledronic Acid (ZA) (50 µM) 
for 48h. F) Lysates of tumours from control (saline) or zoledronic acid-treated mice 
were immunoblotted to detect p53 expression.  
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Figure 12. Geranylgeranyl pyrophosphate mediates mevalonate-dependent mutant 
p53 stabilization.  
(A) Schematic overview of the mevalonate pathway. Enzymes are shown in red and 
inhibitors in blue. (B) Western blot of p53 levels in MDA-MB-231cells untreated (-) or 
treated with different inhibitors: cerivastatin (CER) 1µM, Zoledronic Acid (ZA) 50µM, 
geranylgeranyl transferase I inhibitor (GGTI-298) 1µM, squalene synthase inhibitor 
(YM-53601) 20µM, farnesyl transferase (FTI-277) inhibitor 20µM, for 48 h. (C) Mutant 
p53 was immuniprecipitated from lysates of MDA-MB-231 cells untreated (-) or treated 
(+) with GGTI-298 1µM for 24h. Co-immuniprecipitated Hsp90 was detected by 
western blot. (D) Western blot analysis of p53 levels in MDA-MB-231 cells treated 
with Cervistatin 1µM (CER) alone or with geranygeranyl pyrophosphate (GGPP) 20µM 
for 48h. (E) Schematic representation of geranyl-geranylation of Rho-GTPases. (F) 
MDA-MB-231 cells stably expressing the construct (pLPC-GFP-RhoA-F) coding for a 
mutant RhoA bearing a farnesylation consensus sequence (Cys-Val-Leu-Ser). Cells 
were left untreated (-) or treated with GTI-298 1 µM or with Cerivastatin 1 µM for 48h 
(G) Western blot of p53 levels from MDA-MB-231 cells stably expressing RhoA-F and 
treated with GTI-298 1µM for 48h.  
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Figure 13. Statins exert antitumour effects preferentially in mutant p53-
harbouring tumour cells. 
(A-B) Colony formation assay. The indicated cell lines were treated with Cerivastatin 
(CER) 0,1µM alone or in combination with geranygeranyl pyrophosphate (GGPP) 
20µM for 6 days. Quantification (A) and representative images (B) are shown. The 
status of p53 in the different cell lines is indicated. Error bars represent mean ± s.d. 
from n=3 biological replicates. (C) Quantification of BrdU-positive cells. The indicated 
cell lines were treated with Cerivastatin (CER) 0,1 µM for 24h. Error bars represent 
mean ± s.d. from n=3 biological replicates. (D) Cleaved caspase 3 protein levels are 
show by western blot analysis. MDA-MB-231 cells were left untreated (-) or treated 
with Cerivastatin (CER) 0,1 µM for 96 h. (E) MDA-MB-231 cells were transfected with 
control siRNA (siCTL) of with p53 siRNA for 24h. After 24h cells were left untreated 
(NT) or treated with Cerivastatin 1µM for 48h. 
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Figure 14. Statins counteract mutant p53 gain-of-function in cancer cells. 
(A) Schematic representation of the pro-oncogenic role of Pin1 on mutant p53 activity. 
(B) Relative mRNA levels of SHARP1 and CCNG2 genes in MDA-MB-231 cells non-
treated (NT) or treated with Cerivastatin (CER) alone or in combination with mevalonic 
acid (MVA) for 48h. (C) Relative mRNA levels of mutant p53/Pin1 target genes 
(DEPDC1, BUB1,CCNE2, CENPA, FAM64A) in MDA-MB-231 cells non-treated (NT) 
or treated with Cerivastatin 1μM (CER) alone, or in combination with mevalonic acid 
(MVA) for 48h. (D) DEPDC1 protein levels were analyzed by western blot analysis. 
MDA-MB-231 cells untreated (NT) or treated with Cerivastatin (CER) 1 μM for 48h. 
(E) Transwell migration assays of MDA-MB-231. Cells were treated with Cerivastatin 
1 µM for 24h, then plated for transwell assay and allowed to migrate for 12h. 
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Supplementary Figure.  
(A) Schematic representation of the high-content screening. MDA-MB-231 cells were 
seeded in 384-well plates and 24h later the FDA-approved compounds were added to 
cells at 1 or 10 uM. 24h after the treatment, cells were fixed and processed for 
immunofluorescence for p53 and stained with Hoechst. (B) p53 protein levels were 
analyzed by western blot after treatment with Simvastatin 1 µM for 48 h. (C) Schematic 
representation of GFP–RhoA with a geranylgeranylation consensus sequence (Cys-Leu-
Val-Leu) and the mutant GFP–RhoA-F with a farnesylation consensus sequence (Cys-
Val-Leu-Ser)  
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